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Abstract 
 
Tobacco smokers are at increased risk for the development and progression of chronic 
pain, and smokers with co-occurring pain tend to report greater difficulty and less confidence in 
quitting. Smokers in pain face unique cessation challenges and may benefit from tailored 
interventions that address smoking in the context of pain. This pilot study is the first to test the 
effects of an intervention tailored for smokers with co-occurring pain on motivation to quit and 
engage cessation treatment. Smokers with chronic pain (N = 76, 57.9% Female, 52.6% White, 
Mcpd = 17.64) were randomly assigned to either the tailored or control intervention. Results 
indicated that the tailored intervention (vs. control) increased knowledge of pain-smoking 
interrelations, motivation to quit smoking, desire to quit, and expected success in quitting (ps < 
.01). Participants who received the tailored intervention were also more likely to accept 
information about available smoking cessation treatments (p = .015), and to report interest (p = 
.006) and intention to engage treatment in the next month (p = .003). Effects of the tailored 
intervention on desire to quit and willingness to learn about cessation treatments were mediated 
by increased knowledge of pain-smoking interrelations. At one-month follow-up, treatment gains 
in knowledge of pain-smoking interrelations were maintained (p = .009), and participants who 
received the tailored intervention were more likely to report having subsequently talked to their 
doctor about smoking (p = .034). These data support the notion that smokers with co-occurring 
pain may benefit from interventions that have been tailored to address tobacco smoking in the 
context of pain. Collectively, these findings suggest that smokers with co-occurring pain may 
become more motivated to quit and engage cessation treatment as they become aware of how 
continued smoking may be incongruent with their desired pain outcomes. 
 
  
INCREASING CESSATION MOTIVATION AND TREATMENT ENGAGEMENT AMONG 
SMOKERS IN PAIN 
 
 
 
by 
 
EMILY L. ZALE 
 
 
B.A., University of Rochester, 2007 
M.S., Texas A&M University, 2012 
 
 
Dissertation  
Submitted in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy in Clinical Psychology 
 
 
Syracuse University 
June 2017 
 
 
 
 
  
 
 
 
 
 
 
Copyright © Emily L. Zale 2017 
All Rights Reserved 
 
 
iv 
 
Table of Contents 
 
 
 Page 
Table of Contents................................................................................................................... iv 
List of Tables.......................................................................................................................... v 
List of Figures........................................................................................................................ vi 
List of Appendices.................................................................................................................  vii 
  
Chapters  
I. Introduction......................................................................................................................... 1 
II. Method............................................................................................................................... 5 
III. Results.............................................................................................................................. 20 
IV. Discussion........................................................................................................................ 24 
Footnotes................................................................................................................................ 32 
Tables..................................................................................................................................... 33 
Figures.................................................................................................................................... 44 
Appendices............................................................................................................................. 47 
References.............................................................................................................................. 83 
Vita......................................................................................................................................... 106 
  
  
  
v 
 
List of Tables 
 
Table Page 
 
1. Sociodemographic, Smoking, and Pain Characteristics at Baseline ............................... 33 
 
2. Participant Responses to Items used to Assess Knowledge of Pain-Smoking 
Interrelations at Baseline, Post-Intervention, and One-Month Follow-Up…………… 35 
 
3. Unadjusted Means and Standard Deviations of Continuous Outcome Variables  
at All Time Points ...........................................................................................................  37 
4. Adjusted Means and Standard Errors of Continuous Outcome Variables at  
Post-Intervention ............................................................................................................. 
 
38 
5. Intercorrelations between Measures of Motivation to Quit Smoking at Baseline……...  39 
6. Post-Intervention Willingness to Learn About, Interest in, and Intention to Engage 
Available Smoking Cessation Treatments ...................................................................... 
 
 
40 
7. Participant Comments about the Tailored Intervention .................................................. 41 
8. Participant Satisfaction with the Tailored and Control Interventions ............................. 32 
  
  
  
  
  
  
  
  
  
  
  
  
vi 
 
  
 
 
List of Figures 
 
  
Figure  Page 
 
1. Study Timeline ................................................................................................................ 43 
2. CONSORT Diagram of Study Flow ............................................................................... 44 
3. Post-Intervention Mean Knowledge of Pain-Smoking Interrelations,  
and Motivation to Quit Smoking .................................................................................... 
 
45 
4. Conceptual model of indirect associations between the tailored intervention  
and post-intervention outcomes via increased knowledge of pain-smoking 
interrelations .................................................................................................................... 46 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
vii 
 
List of Appendices 
  
Appendix Page 
A. Measures ......................................................................................................................... 47 
B. Therapist Guide for the Tailored Intervention ................................................................ 77 
C. Psychoeducation Handout for the Tailored Intervention ................................................ 78 
D. Therapist Guide for the Control Intervention ................................................................. 79 
E. Tailored Intervention Fidelity Checklist ......................................................................... 80 
F. Control Intervention Fidelity Checklist .......................................................................... 81 
E. Smoking Cessation Resources Handout ......................................................................... 82 
  
  
  
  
  
  
  
  
  
  
  
 
1 
 
 
 
Increasing Cessation Motivation and Treatment Engagement among Smokers in Pain 
Tobacco use remains the leading preventable cause of mortality in the United States 
(US), accounting for an estimated 448,000 deaths and nearly $289 billion in health-related 
economic losses annually (DHHS, 2014). Despite the known health risks, including multiple 
forms of cancer, cardiovascular diseases, and respiratory diseases (DHHS, 2004), nearly 36 
million American adults (15.1%) continue to smoke cigarettes (Jamal et al., 2016). Like 
smoking, pain is a critical national health problem that affects over 100 million adults at an 
annual cost in excess of $560 billion (IOM, 2011). Estimates derived from nationally-
representative and clinical pain samples suggest that the prevalence of tobacco smoking among 
persons with co-occurring pain may be greater than twice the rate observed in the general 
population (28%-68%; Goesling, Brummett, & Hassett, 2012; Michna et al., 2004; Orhurhu, 
Pittelkow, & Hooten, 2015; Patterson et al., 2012).  
Despite recent declines in smoking prevalence among US adults, there remain subgroups 
of smokers that evince substantially greater smoking prevalence and tobacco-related health 
disparities (Borrelli, 2010). The hardening hypothesis posits that remaining smokers may be 
“burdened” by characteristics that make continuous abstinence more difficult (Hughes & 
Brandon, 2003) or recalcitrant to quitting (Augustson & Marcus, 2004; Irvin & Brandon, 2000). 
A growing body of evidence indicates that interrelations between pain and smoking are 
reciprocal in nature, ultimately resulting in greater pain and the maintenance of smoking (e.g., 
Ditre, Brandon, Zale, & Meagher, 2011; Zale, Maisto, & Ditre, 2016). As such, smokers in pain 
likely represent an important subgroup, which faces unique smoking-related health disparities 
and may benefit from tailored interventions that address smoking in the context of pain (Ditre et 
al., 2011; Zale, Ditre, Dorfman, Heckman, & Brandon, 2014).  
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Several converging lines of evidence indicate that tobacco smoking contributes to the 
onset and progression of chronic pain and interferes with pain treatment. First, smoking has been 
identified as a unique risk factor in the development of rheumatoid arthritis (DHHS, 2014) and 
chronic low-back pain (Shiri, Karppinen, Leino-Arjas, Solovieva, & Viikari-Juntura, 2010), and 
smoking has been associated with the prevalence/severity of numerous other painful conditions 
(e.g., Aamodt, Stovner, Hagen, Brathen, & Zwart, 2006; Amin et al., 2007; Lee et al., 2010; 
Patel et al., 2006; Winn, 2001). Among treatment-seeking pain patients, smokers consistently 
report greater pain intensity and pain-related disability than nonsmokers (e.g., Hooten, Shi, 
Gazelka, & Warner, 2011; Weingarten et al., 2008; Weingarten et al., 2009), and there is some 
evidence that pain and disability may be even more pronounced among smokers who are more 
dependent on tobacco (Hahn, Rayens, Kirsh, & Passik, 2006; Hooten, Shi, et al., 2011). Tobacco 
smoking has been shown to decrease the efficacy of pharmacologic and surgical pain treatments 
(e.g., Glassman et al., 2007; Harty & Veale, 2010), and smokers are less likely to complete 
treatment for chronic pain than nonsmokers (Hooten, Townsend, Bruce, & Warner, 2009). 
Smokers are also more likely to continue to experience pain-related distress and disability 
following pain treatment (Fishbain et al., 2008; Hooten, Townsend, Bruce, Schmidt, et al., 2009). 
A growing body of research further suggests that smokers with co-occurring pain face 
unique challenges to smoking cessation. Experimental evidence indicates that the experience of 
pain can increase urge to smoke and motivate smoking behavior (Ditre & Brandon, 2008; Ditre, 
Heckman, Butts, & Brandon, 2010), episodes of increased pain have been shown to precede 
bouts of cigarette smoking (Dhingra et al., 2013), and smokers with chronic pain consistently 
endorse smoking in response to their pain (Jamison, Stetson, & Parris, 1991; Patterson et al., 
2012). Treatment-seeking pain patients have also identified distraction from physical pain and 
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pain-related distress as a primary smoking motive (Aimer et al., 2015; Hooten, Vickers, et al., 
2011). With regard to smoking cessation, smokers with co-occurring pain report greater 
difficulty and less confidence in quitting (Ditre, Langdon, Kosiba, Zale, & Zvolensky, 2015; 
Zale et al., 2014) and may be less likely to achieve long-term smoking abstinence (Aigner et al., 
2017; Waldie, McGee, Reeder, & Poulton, 2008). Experimental pain reactivity has also been 
shown to predict relapse to smoking (Nakajima & al'Absi, 2011), and greater pain-related 
anxiety has been shown to predict early lapse and relapse to smoking in the context of a self-
guided quit attempt (LaRowe, Langdon, Zvolensky, Zale, & Ditre, in press). Despite the 
possibility that co-occurring pain may impede smoking cessation, there is some evidence that 
smokers may experience clinically-meaningful reductions in pain severity after quitting (Behrend 
et al., 2012).   
Although more than 70% of all smokers endorse a desire to quit smoking (Fiore et al., 
2008), the vast majority (~90%) are not yet ready to make a serious cessation attempt (Herzog & 
Blagg, 2007; Lichtenstein & Hollis, 1992; Pisinger, Jørgensen, Møller, Døssing, & Jørgensen, 
2010). Behavioral and pharmacologic cessation therapies, which have been shown to more than 
double quit rates, remain dramatically underutilized (Babb, Malarcher, Schauer, Asman, & 
Jamal, 2017; CDC, 2011), and engaging smokers in evidence-based treatment has been identified 
as a significant public health priority (USDHHS, 2010). Smokers who are not ready to engage an 
abstinence-oriented treatment may be more amenable to interventions that are designed to 
increase motivation and receptivity towards future cessation treatment (Drake & Mueser, 2000).  
According to a phase-based framework for treating tobacco dependence, the process of 
smoking cessation is comprised of four phases (i.e., Motivation, Precessation, Cessation, 
Maintenance) that present unique opportunities for intervention (Baker et al., 2011). Smokers 
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who are unwilling to make a serious quit attempt can be classified in the Motivation Phase of 
smoking cessation. At the Motivation Phase, smokers should receive treatment designed to 
increase the likelihood of future cessation attempts (Baker et al., 2016), and treatment effects 
may be most appropriately assessed via self-report and behavioral indices of motivation to quit 
(Baker et al., 2011). Prior research has demonstrated that psychoeducation regarding smoking-
health interactions may increase motivation to quit smoking (e.g., McCaul et al., 2006; 
Zvolensky, Lejuez, Kahler, & Brown, 2003), and guidelines for brief motivational substance-use 
interventions indicate that all patients should be educated about relations between substance use 
and co-occurring medical conditions (SAMHSA, 2012).  
Given emerging evidence of reciprocal relations between pain and smoking behavior, 
researchers have suggested that smokers with co-occurring pain may benefit from tailored 
interventions that address smoking in the context of pain (Ditre et al., 2011; Zale et al., 2014). 
Smokers receiving treatment for chronic pain have indicated that they think providing messages 
about pain and smoking (i.e., smoking may impede recovery) could be helpful in motivating 
other patients to reduce their smoking (Kaye, Prabhakar, Fitzmaurice, & Kaye, 2012). A recent 
pilot investigation of a smoking cessation treatment for pain patients found that an intensive 7-
session intervention, which was comprised of both individual and group cognitive behavioral 
therapy, was efficacious in promoting smoking abstinence (Hooten et al., 2014). However, to 
date, no studies have tested a tailored intervention for smokers in pain who are not yet ready to 
engage a serious cessation attempt.  
The objective of this study was to develop and pilot test a brief (i.e., single session) 
intervention, which has been tailored to address smoking in the context of pain, for smokers with 
chronic pain who are not ready to quit. Consistent with a phase-based approach (i.e., treatment at 
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the Motivation Phase), the goals of the tailored intervention were to: (1) educate patients about 
pain-smoking interrelations, (2) increase motivation to engage a serious quit attempt, and (3) 
increase motivation to utilize available smoking cessation treatment. We conducted a pilot 
randomized controlled trial of the brief tailored intervention versus the standard of care that is 
recommended by US Department of Health and Human Services (DHHS) Clinical Practice 
Guidelines for the Treatment of Tobacco Dependence (Fiore et al., 2008). We hypothesized that 
smokers randomized to the tailored intervention (vs. control) would: (1) demonstrate greater 
knowledge of pain-smoking interrelations, (2) self-report greater motivation to quit smoking, (3) 
demonstrate a greater willingness to accept information about smoking cessation treatment, and 
(4) self-report greater intention to utilize existing cessation services. We further hypothesized 
that increased knowledge of pain-smoking interrelations would mediate effects of the tailored 
intervention on motivation to quit smoking and engage cessation treatment. Finally, we 
hypothesized treatment gains in knowledge of pain-smoking interrelations and motivation to quit 
smoking would be maintained at one-month follow-up, and that smokers who received the 
tailored intervention would be more likely to report having subsequently engaged smoking 
cessation treatment.  
Method 
Participants 
 Participants were recruited from the local community via newspaper and internet 
advertisements for a research study about smoking and chronic pain. Respondents were screened 
by telephone for the following inclusion criteria: (1) between 18-65 years of age, (2) currently 
smoking ≥ 10 cigarettes per day; (3) current self-reported moderate-very severe chronic pain; (4) 
average pain intensity of at least 4/10 over the past three months. Given that we sought to recruit 
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smokers who were not yet ready to quit, and therefore could be classified in the Motivation 
Phase of smoking cessation, respondents were excluded if they reported a current active quit 
attempt or use of treatment (i.e., pharmacological or behavioral) to help quit or cut down on 
smoking. Participants who were determined to be eligible by phone screening were scheduled for 
an in-person session. 
Intervention Development 
Development of the tailored intervention was informed by a growing empirical literature 
on interrelations between pain and smoking (e.g., Ditre et al., 2011), theories of health behavior 
change, SAMSHA recommendations for the development of brief interventions (SAMHSA, 
2012), and Clinical Practice Guidelines for the Treatment of Tobacco Dependence (Fiore et al., 
2008). The Clinical Practice Guidelines recommend that smokers who are not ready to make a 
quit attempt should receive brief interventions to promote motivation to quit. Common 
components of evidence-based motivational smoking interventions include: (1) assessment of 
smoking history, substance use, and mood; (2) identification of high risk smoking situations and 
coping skills; (3) application of the FRAMES acronym (provide personalized feedback, advice to 
quit, and a menu of strategies for quitting; emphasize personal responsibility for behavior 
change; enhance self-efficacy; deliver the intervention in an empathic manner); and (4) 
motivational enhancement (Emmons, 2007; Niaura & Shadel, 2007; Perkins, Conklin, & Levine, 
2008). Motivational enhancement represents an adaptation of motivational interviewing that 
incorporates personalized health-related feedback “that is intended to strengthen and consolidate 
commitment to change and promote a sense of self-efficacy” (SAMHSA, 2013). Smokers are 
more likely to engage a quit attempt when they receive even minimal intervention (< 3 minutes), 
7 
 
 
 
and those lasting 30-90 minutes have been shown to increase abstinence rates nearly three-fold 
(Fiore et al., 2008). 
The tailored intervention included a novel psychoeducation component that was informed 
by several theories of health behavior change and empirical evidence that providing smokers 
with an explicit link between continued smoking and illness increases motivation to quit 
(McCaul et al., 2006). First, the Transtheoretical Model (TTM) represents an integrative, 
biopsychosocial approach to conceptualizing health behavior change that has been applied 
extensively to the study of tobacco cessation (Prochaska & DiClemente, 1983; Prochaska, 
Redding, & Evers, 2008). Core components of the TTM include stages of change, which 
classifies readiness to quit smoking according to smokers’ stated intention and measurable steps 
toward quitting, and decisional balance between the perceived positive and negative effects of 
smoking. The TTM predicts that smokers may be motivated to progress from one stage to the 
next as they come to perceive discrepancy between positive and negative effects of smoking. 
Thus, smokers in pain may become more motivated to quit once they perceive a discrepancy 
between continued smoking and their desired pain outcomes.  
Second, the Health Belief Model (HBM) posits that individuals are more likely to change 
an unhealthy behavior if they believe that (a) they are susceptible to negative health outcomes, 
(b) the negative health outcomes will be severe in nature, and (c) behavior change will be 
effective in alleviating or reducing these negative outcomes (Champion & Skinner, 2008). Pain 
has been conceptualized as an aversive state that demands attention and orients behavior towards 
escape/alleviation (Eccleston & Crombez, 1999), and smokers in pain likely hold a salient desire 
for reduced pain and improved functioning. Therefore, a novel psychoeducation component that 
addresses pain-smoking interrelations may increase motivation to quit because: (a) smokers may 
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perceive themselves as immediately susceptible to the negative pain-related effects of smoking, 
(b) pain is likely to be perceived as a severe health outcome, and (c) smokers may come to 
understand the pain-related benefits of quitting.  
A related concept, the “teachable moment,” describes a context or event in which 
behavior change may become more salient due to health concerns, and tobacco use is thought to 
provide a prototypical teachable moment due its broad range of deleterious health effects 
(Lawson & Flocke, 2009). It is our contention that addressing smoking in the context of pain 
may provide an optimal “teachable moment,” as smokers in pain may become more motivated to 
quit if they come to understand the extent to which continued smoking may increase or maintain 
their pain. 
Intervention Conditions 
Active condition (i.e., tailored intervention). Participants randomized to the active 
condition received an intervention that was tailored to address smoking in the context of pain. 
Consistent with existing evidence-based treatments (e.g., Perkins et al., 2008), the tailored 
intervention included personalized feedback and assisted participants in developing discrepancy 
between continued smoking and their health-related goals. The feedback and discrepancy 
components were tailored to address smoking in the context of pain by focusing on pain-smoking 
interrelations (i.e., personalized feedback address both pain and smoking; discrepancy targeted 
pain-related goals). The third component of the active intervention was  anovel pain-smoking 
psychoeducation component, which included information about the deleterious effects of 
smoking on pain and the potential pain-related benefits of smoking cessation. In accordance with 
recommendations for evidence-based brief smoking interventions and motivational 
enhancement, the intervention was delivered in a collaborative, warm, and empathic tone 
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(Emmons, 2007; SAMHSA, 2012). For example, the psychoeducation component was delivered 
using the “elicit – provide – elicit” framework, in which study therapists (1) elicited permission 
to discuss pain/smoking, (2) provided educational information, and (3) elicited feedback from the 
participant about the information that was provided. The therapist guide for the active 
intervention is included in Appendix B and the educational handout is included in Appendix C. 
Control condition (i.e., control intervention). Participants randomized to the control 
condition received a 3As (ask, advise, arrange) intervention, which is an effective smoking 
treatment recommended by Clinical Practice Guidelines (Fiore et al., 2008). Specifically, 
participants were (1) asked about their smoking status and motivation to quit, (2) advised to quit 
smoking, and (3) offered resources to help them quit, including self-help materials (i.e., Clearing 
the Air; National Cancer Institute) that have been widely utilized as a behavioral smoking 
intervention in randomized clinical trials (Lancaster, Stead, Silagy, & Sowden, 2000). The 3As 
intervention is widely used as a standard of care in medical practices, and has demonstrated  
effectiveness for increasing smoking abstinence rates (Fiore et al., 2008). We selected the 3As 
intervention as a control because it allowed us to test whether the tailored intervention improves 
outcomes relative to current practice (Arean & Alvidrez, 2002; Mohr et al., 2009). The therapist 
guide for the control intervention is included in Appendix D. 
Outcome Measures 
 Motivation to quit smoking. Cessation motivation is a multidimensional construct 
(Nezami, Sussman, & Pentz, 2003) that is comprised of both cognitions about quitting (e.g., I 
have a desire to quit smoking) and measurable steps towards behavior change (e.g., seeking 
treatment). Motivation to quit was assessed with three self-report measures that target specific 
and distinct facets of the motivation construct.   
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Thoughts about abstinence. The Thoughts About Abstinence Scale (TAA; Hall, 
Havassy, & Wasserman, 1990) is a reliable and valid measure that uses three separate Numerical 
Rating Scales (NRS) to assess desire to quit smoking (0 = no desire to quit, 10 = full desire to 
quit), anticipated success in quitting (0 = lowest expectation of success, 10 = highest expectation 
of success), and anticipated difficulty quitting (0 = lowest amount of difficulty, 10 = highest 
amount of difficulty). The TAA has previously been used to assess motivation to quit and 
expectations for smoking cessation among smokers in pain (Ditre, Kosiba, Zale, Zvolensky, & 
Maisto, 2016). 
 Contemplation ladder. The contemplation ladder (Biener & Abrams, 1991) is a widely 
used, reliable, and valid measure of motivation to quit smoking on an 11-point Visual Analogue 
Scale (VAS). The contemplation ladder includes anchor points at 0 (no thought of quitting), 2 (I 
think I need to consider quitting someday), 5 (I think I should quit but not quite ready), 8 
(starting to think about how to change my smoking patterns), and 10 (taking action to quit, e.g., 
cutting down, enrolling in a program). The contemplation ladder has previously been used to 
assess motivation to quit among smokers in pain (Zale et al., 2014).  
 Motivation rulers. Motivation rulers for smoking cessation (Boudreaux et al., 2012) 
consist of three separate NRSs that assess importance of quitting (0 = not important at all, 10 = 
most important goal of my life), readiness to quit smoking in the next month (0 = not ready at all, 
10 = 100% ready), and confidence that “you will quit smoking” in the next month (0 = not at all 
confident, 10 = 100% confident). Motivation rulers have previously demonstrated reliability and 
validity for assessing smoking motivation among medical populations (Boudreaux et al., 2012). 
 Knowledge of pain-smoking interrelations. The Pain and Smoking Questionnaire 
(PSQ) is a 25-item questionnaire developed by members of our research team to assess 
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knowledge of interrelations between pain and tobacco smoking. A total of 17 items assess 
knowledge of associations between smoking and multiple health conditions (e.g., lung cancer, 
heart disease, diabetes). Eight separate items assess specific knowledge of pain-smoking 
interrelations, including whether smoking can cause chronic pain, contribute to pain-related 
impairment in functioning, reduce the effectiveness of prescription pain medications, provide 
acute analgesic effects, or help to distract from pain. Pain-specific items also assess knowledge 
of whether pain can motivate smoking behavior or whether quitting smoking is associated with 
improved pain and physical functioning. Response options for each item are yes, no, or not 
sure/don’t know. The PSQ was scored as the number of total pain-smoking items that were 
correctly answered (range 0 – 8), with higher scores representing a greater number of correct 
responses.  
 Cessation treatment engagement. Motivation to engage cessation treatment was 
assessed pre- and post-intervention as (1) willingness to learn about treatment options, (2) 
interest in engaging treatment, and (3) intention to engage treatment in the next 30 days. 
Willingness to engage treatment was assessed with the question “would you like to learn about 
options for treatment to help you quit smoking?” Participants who answered yes were then given 
a list of treatment options (i.e., medication/primary care, Quitline, behavioral health, or none of 
the above), and asked whether they were interested in using any of the treatments and whether 
they planned to enroll in any of the treatments in the next 30 days. Multiple responses were 
permitted. For each question, participants who selected at least one treatment option were 
considered to have indicated interest in treatment and an intention to enroll in treatment, 
respectively. At one-month follow-up, engagement in treatment over the past 30 days was 
assessed (yes/no) for each treatment option. 
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Treatment satisfaction. The Client Satisfaction Questionnaire (Larsen, Attkisson, 
Hargreaves, & Nguyen, 1979) was used to assess satisfaction with the study interventions. The 
CSQ includes individual items that measure perceived quality of the treatment (0 = poor, 3 = 
excellent), satisfaction with the treatment (0 = very dissatisfied, 3 = very satisfied), and whether 
participants felt the treatment was helpful, would seek treatment again or recommend treatment 
to a friend (0 = no, definitely not, 3 = yes, definitely).  
 Perceived discrepancy between smoking and desired pain outcomes. An open-ended 
text box was included for participants to provide comments about reasons why the tailored 
intervention did or did not improve their motivation to quit smoking. Perceived discrepancy 
between smoking and desired pain outcomes was coded as yes/no. Comments were coded as 
indicative of discrepancy only if participants made statements specifically about “pain” or 
“chronic pain.” All other statements, including associations between smoking and general health, 
were coded as not indicative of perceived discrepancy.  
Demographics, Smoking, and Pain History 
 Demographics. The demographics form assessed age, gender, marital status, 
race/ethnicity, education, and household income. This demographics form has been previously 
used to asses sociodemographic characteristics among smokers in pain (Ditre et al., 2015; Ditre, 
Zale, Kosiba, & Zvolensky, 2013; Zale et al., 2014). 
 Smoking history. The Smoking History Form (Brown, Lejuez, Kahler, & Strong, 2002) 
is a widely used assessment of smoking behavior, including smoking rate, age of smoking 
onset/years of smoking, and prior attempts to quit smoking. The Smoking History Form has been 
used previously as a descriptive measure of smoking characteristics among smokers in pain 
(Ditre et al., 2013; Zale et al., 2014).  
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 Exhaled carbon monoxide (CO). Exhaled CO was assessed using the CoVita 
Smokerlyzer Micro+
TM
 (Bedfont Scientific; Haddonfield, NJ). Exhaled CO is a well-established 
and non-invasive objective measure of tobacco smoking (Benowitz et al., 2002; Evans, Sutton, 
Oliver, & Drobes, 2015; Piper & Curtin, 2006), which is highly correlated with smoking 
heaviness and time since last cigarette (Hung, Lin, Wang, & Chan, 2006; Kwok, Taggar, Cooper, 
Lewis, & Coleman, 2014). A cut-off of 4 ppm has been identified as a reliable indicator of 
cigarette use in the previous 24 hours (Cropsey, Eldridge, Weaver, Villalobos, & Stitzer, 2006; 
Javors, Hatch, & Lamb, 2005; Raiff, Faix, Turturici, & Dallery, 2010).  
 Smoking dependence. The Heaviness of Smoking Index (HSI; Heatherton, Kozlowski, 
Frecker, Rickert, & Robinson, 1989) is a two-item measure that assesses time to first cigarette 
after waking and number of cigarettes smoked per day. Responses options are assigned 
numerical values between 0 and 3, and items are summed to generate a total score (range 0-6), 
with higher scores representing greater levels of smoking dependence. The HSI has been shown 
to reliably predict cessation outcomes (Borland, Yong, O'Connor, Hyland, & Thompson, 2010; 
Fagerstrom, 2012), and has been previously used among smokers in pain (Ditre, Kosiba, et al., 
2016). 
 Stages of change. The Stages of Change (SOC; DiClemente et al., 1991) is a three item 
measure that is widely-used to classify motivation to quit smoking according to the 
Transtheoretical Model of Behavior Change (Prochaska & DiClemente, 1983; Prochaska et al., 
2008). The SOC algorithm includes three items, which assess whether participants are seriously 
considering quitting smoking in the next 6 months or the next 30 days and the number of past-
year quit attempts that lasted greater than 24 hours. Participants are classified as in either 
precontemplation (no consideration of quitting), contemplation (consideration of quitting but no 
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past-year quit attempt), or preparation (consideration of quitting in the next 30 days and one or 
more past-year quit attempts). The SOC has previously been used to classify stages of change 
among smokers with chronic pain (Zale et al., 2014).  
Chronic pain grade. The Graded Chronic Pain Scale (GCPS; Von Korff, 2011) is a 
reliable and valid measure of chronic pain severity, which was designed for use both in the 
general population and among treatment-seeking pain patients. The GCPS includes 3 separate 
NRSs (0 = no pain, 10 = pain as bad as could be) that assess pain right now, worst pain in the 
past 3 months, and average pain in the past 3 months, and three 3 separate NRSs (0 = no 
interference, 10 = unable to carry on any activities) that assess pain-related interference with 
daily activities, recreation/social/family activities, and ability to work over the past 3 months. An 
additional item assesses pain-related days of interference in the past 3 months. The GCPS yields 
a characteristic pain intensity score (range 0 – 30), an interference score (range 0 – 40), and a 
classification of chronic pain grade that accounts for both pain intensity and interference (Grade I 
= low intensity/low interference; Grade II = high intensity/low interference; Grade III = high 
disability/moderate interference; Grade IV = severe interference). The GCPS has previously been 
used to assess chronic pain status among smokers in pain (Ditre, Kosiba, et al., 2016; Ditre et al., 
2013), and demonstrated good internal consistency in the current sample (α = .898). 
 Pain history. Descriptive information regarding pain history (e.g., pain duration and 
frequency) and pain treatment (e.g., satisfaction with treatment from doctors and pain 
specialists/pain treatment programs) was assessed using items adapted from the Kansas 
Behavioral Risk Factor Surveillance System (Toblin, Mack, Perveen, & Paulozzi, 2011). 
Participants also indicated the primary source of their pain (e.g., back pain, arthritis/rheumatism, 
migraines) and responded (yes/no) to an item adapted from the National Comorbidity Survey-
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Replication (Kessler et al., 2004), which asked “do you currently have medically unexplained 
chronic pain? This is defined as pain lasting six months or longer that is severe enough to either 
interfere a lot with your normal activities or to cause a lot of emotional distress and that a doctor 
cannot find a physical cause to explain.” 
Potential Covariates 
 Pain and smoking expectancies. The Pain and Smoking Inventory (PSI; Ditre, Zale, 
Heckman, & Hendricks, 2016) is a 9-item measure of perceived interrelations between pain and 
tobacco smoking. Items assess the extent to which participants perceive their own pain and 
smoking to be related across three domains (pain as a motivator of smoking, smoking to cope 
with pain, and pain as a barrier to smoking cessation) using a 7-point Likert scale (0 = not at all 
true, 3 = somewhat true, 6 = extremely true). The total score for the PSI is the average of all 9-
items, with higher scores representing greater perceived relations between pain and smoking 
behavior. The PSI has previously been shown to distinguish between smokers with and without 
chronic pain (Ditre, Zale, et al., 2016), and demonstrated excellent internal consistency in the 
current sample (α = .910).  
 Pain-related anxiety. Pain-related anxiety was assessed using the Pain Anxiety 
Symptoms Scale (PASS-20; McCracken & Dhingra, 2002), which measures the frequency of 20 
prototypical anxious or fearful responses to pain (e.g., I worry when I am in pain; I try to avoid 
activities that cause pain) using a 7-point Likert Scale (0 = never, 6 = always). Greater total 
scores (range 0 – 120) represent greater levels of pain-related anxiety. The PASS-20 has been 
previously used to investigate relations between pain and tobacco smoking among smokers in 
pain (Ditre et al., 2015; Ditre et al., 2013; LaRowe et al., under review), and demonstrated 
excellent internal consistency in the current sample (α = .922).  
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Prescription opioid misuse. The Prescription Opioid Misuse Index (POMI; Knisely, 
Wunsch, Cropsey, & Campbell, 2008) assesses six prototypical signs of opioid misuse (e.g., 
taking more medication than prescribed, feeling high or buzzed after using mediation). 
Responses (0 = no, yes = 1) are summed to generate a total score, with high scores representing 
greater levels of misuse. Consistent with scoring recommendations, a cut-off score of 2 was also 
used to categorize misuse behavior (yes/no). The POMI demonstrated adequate internal 
consistency in the current sample (α = .803). 
 Depression and anxiety symptoms. The Patient Health-Questionnaire-4 (PHQ-4; 
Kroenke, Spitzer, Williams, & Lowe, 2009) is a reliable and valid screening tool for anxiety and 
depression that was designed for use in medical populations. The PHQ-4 consists of two items 
that assess frequency of depression symptoms (i.e., feeling down, depressed or hopeless; little 
interest or pleasure in doing things) and two items that assess frequency of anxiety symptoms 
(i.e., feeling anxious, nervous, or on edge; not able to stop or control worrying) during the past 
two weeks. Response scales range from 0 (not at all) to 3 (nearly every day). Items are summed 
to generate separate scores for depression and anxiety symptoms, with higher scores indicating 
higher symptom severity. Consistent with scoring recommendations, a cut-off score of 3 was 
used to distinguish potential presence of major depression or generalized anxiety, respectively. 
The depression and anxiety symptom scales each demonstrated adequate internal consistency in 
the current sample (α = 782 and α = .826, respectively).   
 Alcohol use. The Alcohol Use Disorders Identification Test-C (AUDIT-C; Bush, 
Kivlahan, McDonell, Fihn, & Bradley, 1998) is a three item self-report measure of alcohol use 
during the past year. Items assess frequency of alcohol consumption, typical amounts of alcohol 
consumed per drinking episode, and frequency of binge (i.e., ≥ 6 drinks in one drinking episode) 
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drinking. The AUDIT-C yields a continuous total score (range 0 – 12), with greater scores 
representing greater levels of alcohol use. Cut-off scores of 4 for men and 3 for women can be 
used to distinguish hazardous drinking. The AUDIT-C demonstrated adequate internal 
consistency in the current sample (α = .865).    
Procedure 
 All procedures were approved by the Institutional Review Board of Syracuse University. 
In person appointments were conducted in the Pain and Addictions Research Lab, which is 
housed within an outpatient medical building. Upon arrival to the in-person session, participants 
provided written informed consent and exhaled CO. Participants then were left alone to complete 
a battery of computerized self-report questionnaires that assessed baseline levels on all outcome 
variables, sociodemographic, smoking and pain characteristics, and potential covariates. 
Following baseline measures, participants were randomized to either the tailored or control 
intervention, and the intervention was delivered face-to-face by a trained study therapist. 
Participants were then left alone to complete the battery of computerized post-intervention 
outcome measures. At the end of the in-person session, participants were provided with a 
reminder card for the one-month telephone follow-up and $25 compensation for their time and 
travel. Participants were contacted via telephone at one-month follow-up, and outcome measures 
were administered verbally by trained research assistants. Research assistants were not informed 
of the participant’s condition assignment prior to conducting the telephone follow-up. Figure 1 
presents a study timeline, and Figure 2 presents the complete flow of participants through the 
study.  
Therapist Training and Treatment Fidelity 
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 The study interventions were delivered by the lead author (ELZ) and another clinical 
psychology doctoral student (MJD). The majority (82.9%) of interventions were conducted by 
the lead author (ELZ). Chi square analysis revealed no differences (p = .07) in the proportion of 
active and control interventions completed by each therapist. Study therapists were trained on all 
protocols by the lead author (ELZ) and the clinical supervisor, who is a licensed Clinical 
Psychologist (JWD). Prior to beginning the study, both study therapists completed multiple role 
plays of the tailored and control interventions. For each participant, study therapists completed 
an intervention checklist during the visit to ensure adherence to the tailored and control 
interventions (see Appendix E and Appendix F, respectively). All intervention sessions were 
audio-recorded, and the study therapists also met regularly to review intervention tapes and 
monitor fidelity.  
Data Analytic Plan 
All analyses were completed using SPSS Version 22 (IBM; 2013). First, group 
differences in baseline variables (e.g., demographics, smoking characteristics, pain 
characteristics) were examined using t-tests and chi-square analyses in order to verify that 
randomization was successful. No differences were observed on any baseline variables (all ps > 
.082).  
Post-intervention outcomes were analyzed with an intent-to-treat approach. Analysis of 
covariance (ANCOVA) and logistic regression were used to test main effects of the intervention 
condition on knowledge of pain-smoking interrelations, motivation to engage a serious quit 
attempt, and intention to engage smoking cessation treatment. Separate ANCOVAs (controlling 
for respective baseline scores) were conducted with intervention condition entered as the fixed 
factor and each continuous outcome (e.g., contemplation ladder) entered as the respective 
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dependent variables. Separate logistic regression models (controlling for respective baseline 
scores) were utilized to test the effects of intervention condition and all dichotomous outcome 
variables (e.g., intention to engage smoking cessation treatment). We then tested increased 
knowledge of pain-smoking interrelations as a mediator of observed effects of treatment 
condition on post-intervention motivation to quit and engage smoking cessation treatment. 
Separate mediation models were tested for each outcome using the PROCESS Macro for SPSS 
(Hayes, 2013), which employs a bootstrapping approach, can accommodate both dichotomous 
and continuous variables, and yields estimates of direct and indirect effects of all predictor and 
mediator variables (Preacher & Hayes, 2008). We also conducted ANCOVA and logistic 
regression analyses (controlling for respective baseline scores) among participants who received 
the tailored intervention to test associations between perceived discrepancy (entered as the fixed 
factor) and each outcome variable.  
One-month follow-up outcomes were analyzed for all participants who provided data (N 
= 59)
1
 using a modified intent-to-treat approach (Gupta, 2011). For continuous variables, 
repeated measures analysis of variance (ANOVA) was used with intervention condition entered 
as the fixed factor, and all three assessment time points (baseline, post-intervention, 1-month 
follow-up) entered as dependent variables. Separate logistic regression models were used to test 
the effects of the intervention on dichotomous behavioral smoking variables (i.e., self-reported 
quit attempt, self-reported use of available treatment resources).  
Results 
Participant Characteristics 
Participants included 76 daily tobacco smokers (57.9% female; 42.1% Black or African 
American; Mage = 42.71, SD = 13.42), who reported smoking approximately 18 cigarettes per day 
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(SD = 10.71) for an average of 26 years (SD = 12.76). The average HSI score was 3.37 (SD = 
1.21), indicating a moderate level of tobacco dependence (e.g., Chaiton, Cohen, McDonald, & 
Bondy, 2007). The majority (59.2%) of participants endorsed having made a serious attempt to 
quit smoking in the past, and 42% of those with a past quit attempt reported that they had never 
received treatment for smoking cessation. With regard to SOC, more than one third of 
participants were classified as precontemplation (35.5%) and one half of participants (51.3%) 
were classified as contemplation.  
The majority of participants reported experiencing chronic pain for at least one year 
(78.9%), and that they were experiencing pain at more than one location in the body (64.5%). 
The most commonly endorsed sources of chronic pain were chronic low back pain (55.3%), 
chronic back pain (46.1%), arthritis/rheumatism (32.9%), and chronic neck pain (31.6%). Mean 
ratings of pain on average over the past 3 months (M = 6.76, SD = 2.08) indicate that the sample 
was experiencing moderate pain that was clinically significant (Krebs, Carey, & Weinberger, 
2007). More than one third of participants reported daily use of pain medications (37.3%), and 
29% reported current use of prescription opioids or narcotic pain medications. 
Sociodemographic, smoking, and pain characteristics are presented in Table 1. 
Post-Intervention Outcomes 
 Knowledge of pain-smoking interrelations. As hypothesized, results of ANCOVA 
indicated that the tailored intervention increased knowledge of pain-smoking interrelations (see 
Figure 3). Of the eight questions on pain-smoking interrelations, participants randomized to the 
tailored intervention correctly answered three more questions than did participants in the control 
condition, F(1,73) = 82.37, p < .001, ɳ
2
p = .53. Participant responses at each time point are 
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presented in Table 2. Unadjusted means and standard deviations for knowledge scores are 
presented in Table 3, and adjusted means and standard errors are presented in Table 4. 
 Motivation to quit smoking. As hypothesized, ANCOVA revealed that the tailored 
intervention increased multiple indices of cessation motivation (see Table 4). Specifically, 
participants randomized to the tailored intervention scored higher on the contemplation ladder, 
F(1,73) = 11.54, p = .001, ɳ
2
p = .14, and reported greater desire to quit smoking, F(1,73) = 7.40, 
p = .008, ɳ
2
p = .09. The tailored intervention also increased expected success in quitting, F(1,73) 
= 12.95, p = .001, ɳ
2
p = .15. A trend-level association was observed for greater confidence in 
quitting among participants who received the tailored intervention F(1,73) = 3.68, p = .059, ɳ
2
p = 
.05. No group differences were observed with regard to self-reported importance (p = .237), 
readiness (p = .138), or anticipated difficulty quitting (p = .703). Intercorrelations between 
baseline measures of motivation to quit smoking are presented in Table 5. 
 Motivation to engage cessation treatment. As hypothesized, results of logistic 
regression revealed that the tailored intervention increased willingness to learn about cessation 
treatments (Wald χ
2
 = 5.91, p = .015). Participants randomized to the tailored intervention were 
also more likely to indicate that they would be interested in using cessation treatment in the 
future (Wald χ
2
 = 7.70, p = .006), and that they intended to engage treatment in the next 30 days 
(Wald χ
2
 = 9.06, p = .003). Follow-up analyses revealed that the tailored intervention increased 
interest and intention to engage the Quitline and talk to their doctor/mediation (see Table 6).  
Knowledge of pain-smoking interrelations as a mediator of post-intervention 
outcomes. As depicted in Figure 4, we observed an indirect effect of the tailored intervention on 
greater desire to quit (b = .84, SE = .45, 95% CI [0.03, 1.81]) and willingness to learn about 
cessation treatments (b = 2.66, SE = 1.46, 95% CI [0.13, 4.90]) via increased knowledge of pain-
22 
 
 
 
smoking interrelations. Increased knowledge of pain-smoking relations did not mediate treatment 
effects on contemplation ladder scores (b = .31, SE = .60, 95% CI [-0.92, 1.44], expected success 
in quitting (b = .15, SE = .52, 95% CI [-0.97, 1.12]), or intention to engage cessation treatment (b 
= .86, SE = .72, 95% CI [-0.52, 2.36]).  
Perceived discrepancy between continued smoking and desired pain outcomes. The 
majority (n = 32) of participants in the active intervention provided comments about why the 
intervention did or did not increase motivation to quit smoking (see Table 7). All participants 
who provided feedback that indicated discrepancy (n = 13) between continued smoking and 
desired pain outcomes also reported that the intervention helped to increase their motivation to 
quit smoking. However, no differences were observed on any outcome variables between 
participants who did and did not report discrepancy (all ps > .149).  
One-Month Follow-Up Outcomes 
 Participant characteristics. A total of 59 (78%) participants provided data at one-month 
follow-up. There was no association between intervention condition assignment and loss to 
follow-up (χ
2
 = 1.89, p = .169), indicating that attrition did not differ between groups. The 
primary reasons for loss to follow-up were disconnected/out of service telephone number 
(58.8%) and did not return multiple voicemail messages (29.4%). Examination of baseline 
variables revealed that participants who provided follow-up data were older (M = 44.64, SD = 
12.98) than participants who did not provide follow up data (M = 36.29, SD = 13.27), t(74) = 
2.32, p = .023. Participants who provided follow-up data also reported smoking fewer cigarettes 
per day at baseline (M = 15.98, SD = 9.17), relative to those who did not provide follow-up data 
(M = 23.41, SD = 12.70), t(74) = 2.61, p = .011.  
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 Smoking behavior and engagement of smoking cessation treatment. Results of 
logistic regression revealed that participants who received the tailored intervention were more 
likely to report having subsequently talked to their doctor about smoking (OR = 4.12, 95% CI 
[1.12, 15.21], Wald χ
2
 = 4.51, p =.034), relative to participants who received the control 
intervention. Although four participants who received the tailored intervention reported having 
quit smoking (vs. zero in the control condition), results of logistic regression indicated that 
smoking status did not significantly differ between the two groups (p = .691). On average, 
participants in both conditions reported smoking a similar number of cigarettes per day at follow-
up (p = .387), and no differences were observed with regard to the number of participants who 
reported cutting down on their smoking (p = ..739) or making a 24 hour quit attempt (p = .188).  
Maintenance of treatment gains. Repeated measures ANOVA revealed that participants 
who received the tailored intervention continued to report greater knowledge of pain-smoking 
interrelations at one-month follow-up (M = 6.00, SE = .42), relative to participants who received 
the control intervention (M = 4.43, SE = .40), F(1, 49) = 7.46, p = .009, ɳ
2
p = .13. No group 
differences were observed in contemplation ladder scores (p = .18), reported desire to quit (p = 
.83) or expected success in quitting (p = .16). 
Intervention Satisfaction  
Participants who received the tailored intervention reported a greater mean level of 
satisfaction, relative to participants who received the control intervention, t(74) = 3.15, p = .002. 
Participants in the tailored intervention also reported that they would be more likely to seek the 
intervention again in the future, t(74) = 2.09, p = .040, and to recommend the intervention to a 
friend, t(74) = 3.44, p = .001. The majority of participants who received the tailored intervention 
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rated the handout as extremely helpful (60.5%) and easy to understand (76.3%). Complete 
satisfaction ratings for the tailored and control interventions are presented in Table 8. 
Discussion 
Pain and tobacco smoking are highly comorbid critical national health problems, and 
smokers may constitute a recalcitrant subgroup who face unique cessation challenges and could 
benefit from tailored interventions (e.g., Borrelli, 2010; Ditre et al., 2011; Zale et al., 2014; Zale 
et al., 2016). This is the first randomized controlled trial of a motivational intervention that has 
been tailored to address smoking in the context of pain. Informed by existing evidence-based 
interventions and empirical and theoretical conceptualizations of health behavior change, the 
tailored intervention included a novel psychoeducation component that was designed to increase 
knowledge of pain-smoking interrelations and assist smokers in developing discrepancy between 
continued smoking and desired pain outcomes. When compared to a 3As intervention that is 
recommended by Clinical Practice Guidelines and used in many medical settings as the standard 
of care (Fiore et al., 2008), the tailored intervention increased knowledge of pain-smoking 
interrelations, motivation to quit smoking, willingness to learn about smoking cessation 
treatment, and intention to engage cessation treatment. At one-month follow up, treatment gains 
in knowledge of pain-smoking interrelations were maintained, and participants who received the 
tailored intervention were more likely to report having subsequently talked to their doctor about 
smoking.  
The tailored intervention included a novel psychoeducation component that provided 
participants with clear and explicit links between smoking behavior and pain-relevant 
processes/outcomes. At baseline, participants answered an average of 3/8 questions about pain-
smoking interrelations correctly, and the majority were unaware that smoking can cause chronic 
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pain (59.2%), contribute to greater pain intensity (56.5%), or reduce the effectiveness of 
prescription pain medications (75%). Participants who received the active intervention 
demonstrated significant increases in knowledge of pain-smoking interrelations, correctly 
answering 6/8 questions at post-intervention and one-month follow-up. Thus, results suggest that 
smokers are responsive to psychoeducation about complex associations between pain and 
tobacco, and that smokers with chronic pain are able to learn and retain new information about 
how smoking and pain are interrelated. 
The tailored intervention (vs. 3As control) increased multiple self-report and behavioral 
indices of motivation to quit smoking at post-intervention. Specifically, the tailored intervention 
increased desire to quit smoking, contemplation ladder scores, and expected success in quitting. 
Participants who received the tailored intervention were also more likely to demonstrate 
willingness to learn about cessation treatments, interest in cessation treatment, and intention to 
engage treatment in the next month. Increased knowledge of pain-smoking interrelations 
mediated observed effects of the tailored intervention on increased desire to quit smoking and 
willingness to learn about treatment options. Taken together, these findings are consistent with 
evidence that providing smokers with clear and explicit links between smoking and health can 
increase motivation to quit smoking (McCaul et al., 2006), and that smokers who are not yet 
ready to quit may be amenable to interventions designed to increase motivation to quit and 
engage abstinence-oriented treatment (Drake & Mueser, 2000). 
At one-month follow-up, participants who received the tailored intervention were more 
likely to report having subsequently engaged cessation treatment. Indeed, 37% of participants 
who received the tailed intervention reported talking to their doctor about smoking (vs. 12.5% of 
participants who received the 3A’s control). This finding could reflect greater initiative on the 
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part of participants who received the tailored intervention to engage with their healthcare 
provider.  Given that Clinical Practice Guidelines recommend all smokers receive a brief 
smoking intervention at every physician visit (Fiore et al., 2008), it is also possible that this 
finding reflects greater receptivity towards interventions initiated by a healthcare provider. In 
either case, these results provide initial evidence that the tailored pain-smoking intervention 
increased willingness to engage future cessation treatment. 
Results of the current study contribute to a growing multidisciplinary literature 
examining pain-smoking interrelations, and suggest that smokers may become more motivated to 
quit as they become aware of how continued tobacco smoking may interfere with their desired 
pain outcomes. Results also indicate that a single, brief (i.e., 30 minute) session may be sufficient 
to increase motivation to quit smoking and engage smoking cessation treatment among smokers 
in pain. The tailored intervention was designed to be easily implemented in integrated health care 
models (Funderburk et al., 2010; James & Folen, 2005), and it is possible that the intervention 
could be employed in medical settings as a means of motivating smokers to quit and connecting 
them to additional treatment (e.g., smoking cessation medications) in real time. Indeed, previous 
work has demonstrated that smokers with chronic pain are amenable to pharmacologic smoking 
interventions (Zale & Ditre, 2013), and talking to your doctor or using medication was the most 
popular cessation treatment option selected by participants in the current study. Among 
participants who received the tailored intervention, 76% were interested in talking to their 
doctor/medication, 65% indicated that they intended to engage that treatment in the next 30 days, 
and 37% reported having talked to their doctor about smoking at one-month follow-up. Thus, 
these findings suggest that smokers with chronic pain may be receptive to tailored smoking 
interventions that are designed to promote ongoing engagement with the healthcare system. 
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Findings that the tailored pain-smoking intervention increased interest and willingness to 
engage cessation resources are particularly relevant, given that the tailored intervention did not 
increase self-reported readiness to quit. Evidence-based abstinence interventions assist patients 
in preparing for a quit attempt by setting a quit date, removing smoking related triggers, and 
developing strategies for coping with cravings and withdrawal symptoms (Cahill, Lancaster, & 
Green, 2010; Perkins et al., 2008). Although participants who were willing to learn about 
smoking cessation resources received a description of abstinence-oriented approaches (see 
Appendix G), neither study intervention included a component specifically designed to support 
smoking abstinence. Although results of the current study indicate that the tailored pain-smoking 
intervention has the potential to increase multiple facets of motivation to quit smoking, and 
additional abstinence-specific treatment components may be needed to increase readiness to 
engage a serious quit attempt.  
It is also notable that participants in the current study reported fairly low levels of formal 
education, such that 40% of participants did not hold a high school diploma or GED. Although 
the national prevalence of smoking has declined in the US, there remain significant disparities as 
a function of educational achievement. In the general population, the prevalence of smoking 
among persons who completed 9
th
-11
th
 grade (31.6%) or received a GED (34.1%) is more than 
double the national rate (15.1%), and when stratified by educational attainment, persons without 
a high school diploma are the only group to have demonstrated an increase in smoking 
prevalence over the past decade (Jamal et al., 2016). Thus, participants in the current study are 
likely representative of a substantial portion of the smoking population. Persons with lower 
levels of educational attainment are also more likely to demonstrate low levels of health literacy 
(i.e., the ability process, understand, and use health information) and may have difficulty 
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communicating with healthcare providers (DHHS, 2008). Indeed, when treating patients with 
low health literacy, providers tend to endorse low perceived effectiveness and may be reluctant 
to offer health education to their patients (Seligman et al., 2005). Results of the current study are 
encouraging because they suggest that low levels of educational attainment are not a barrier to 
learning or retaining information about complex pain-smoking relations.  
Clinical implications of this study include the possibility that health care providers may 
use pain as a “teachable moment” to discuss smoking cessation with their patients. Consistent 
with a phase-based framework for smoking cessation (Baker et al., 2011), healthcare providers 
who deliver the tailored intervention should consider greater motivation towards smoking 
cessation to be a successful treatment outcome. When possible, providers could capitalize on 
increased motivation to quit and engage cessation treatment in real-time by immediately linking 
patients to additional services. For example, healthcare providers can recommend cessation 
medications, provide brief evidence-based behavioral interventions to support readiness to quit 
(e.g., strategies for coping with cravings; Fiore et al., 2008) and proactively connect patients to 
ongoing behavioral support via their state Quitline (i.e., via electronic Refer-to-Quit).  
Results of the current study also have the potential to inform future research. First, a fully 
powered clinical trial is needed to test the effectiveness of the tailored intervention in outpatient 
medical settings. Such a trial could utilize medical record review to verify chronic pain status 
and utilization of cessation treatments, as well as collect more detailed follow-up data over 
multiple assessment points (e.g., number of doctor visits). An effectiveness trial that seeks to 
evaluate delivery of the tailored intervention in a medical setting could also include a separate 
component designed to educate providers about pain-smoking interrelations and train providers 
to talk with their patients about pain and smoking. Second, future clinical trials should utilize a 
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control condition that includes a motivational intervention without the tailored pain-smoking 
psychoeducation component (e.g., an intervention that provides general health education). Use of 
an untailored control intervention that also targets similar motivational processes (e.g., increased 
knowledge, perceived discrepancy) would allow for tests of the relative effects of pain-specific 
content above-and-beyond effects of the general motivational components. Third, future research 
should test whether booster sessions (e.g., in person or via telephone) help to maintain treatment 
gains in motivation and desire to quit smoking. There is some evidence to suggest that shorter 
visits at greater frequency contribute to improved cessation outcomes (Fiore et al., 2008), and 
future research should test the optimal duration and frequency for delivery of the tailored 
intervention. Fourth, future research should test the potential utility of further modifying the 
tailored intervention, which was tailored to address smoking in the context of pain among 
smokers not yet ready to quit, to match participant’s specific stage of change (e.g., pre-
contemplation via contemplation) at baseline. Finally, future research should examine the utility 
of delivering a similar intervention via methods that are more cost effective and do not require 
effort from specialized providers, including internet and smart-phone based interventions 
(Cunningham, 2007; Riper et al., 2009).  
 Strengths of the current study include assessment of multiple self-report and behavioral 
indices of motivation to quit smoking, use of empirical and theoretical conceptualizations of 
health behavior change to inform treatment development, and recruitment of a generalizable 
sample of daily tobacco smokers. The current study also recruited participants who were not 
seeking treatment for smoking cessation, which may increase generalizability to smokers who 
could encounter the tailored intervention in the course of seeking other healthcare services (e.g., 
at a regularly scheduled primary care appointment). Despite these strengths, several limitations 
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should be acknowledged. First, participants were recruited from the community, and we were 
unable to verify their chronic pain status via medical record review. Second, although research 
assistants conducted telephone follow-ups, study therapists conducted the in-person research 
visits, which may have produced demand effects or desirability bias in participant responses. 
However, we sought to limit these potential effects by leaving participants alone to complete 
computerized assessments at pre- and post-intervention and assuring participants that all 
responses were confidential. Third, we conducted a single follow-up assessment at one-month, 
which may not have provided sufficient time for participants to engage medical services, and it is 
not known whether participants in both conditions had equal opportunities to engage the 
healthcare system during the follow-up period. Fourth, we tested the tailored intervention against 
a 3As intervention that is recommended by Clinical Practice Guidelines and widely used in 
medical practices (Fiore et al., 2008), which allows for conclusions about how the tailored 
intervention performed relative to an intervention that participants are likely to receive in the 
healthcare setting. However, it is not known whether the tailored intervention would serve to 
increase motivation to quit and engage treatment above-and-beyond an untailored motivational 
intervention that provides general health information (i.e., is not tailored to address pain-smoking 
interrelations). Finally, although the 30-minute intervention is consistent with typical visit length 
for integrated healthcare settings (Funderburk et al., 2010), it may be too long to deliver within a 
standard medical appointment (Tai-Seale, McGuire, & Zhang, 2007). It is possible that the 
tailored intervention may require additional adaptation (e.g., changes to visit length or 
frequency) to achieve optimal feasibility and effectiveness in medical settings.  
  Taken together, results of the current study indicate that smokers with chronic pain may 
become more motivated to quit smoking and engage cessation treatment as they become more 
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aware of how continued smoking may contribute to deleterious pain outcomes. These findings 
contribute to an emerging literature on complex pain-smoking interrelations, and provide initial 
support for the hypothesis that smokers with chronic pain may benefit from interventions that 
have been tailored to address smoking in the context of pain. As such, the current results have 
the potential to inform the treatment of smokers with chronic pain, including the ongoing 
development of tailored interventions for this important subpopulation of smokers. 
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Footnotes 
 
1
 Multiple imputation was considered as an alternative to restricting analyses to 
participants who provided follow-up data. However, when multiple imputation was used, linear 
mixed modeling revealed a similar pattern of results. Little’s MCAR test also indicated that data 
were missing completely at random (p = .464). Given recommendations that pairwise or listwise 
deletion can be used instead of imputation when data are MCAR (Garson, 2015), and evidence 
from Monte Carlo Simulations that ANOVA performs similarly when samples are restricted to 
complete data (Cheema, 2014), we elected to report results of analyses among participants who 
provided follow-up data. 
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Table 1 
Sociodemographic, Smoking, and Pain Characteristics at Baseline 
 
 Intervention Condition  
 Tailored 
(n = 38) 
Control 
(n = 38) 
Total Sample 
(N = 76) 
 n (%) n (%) n (%) 
Gender    
     Male 17 (44.7%) 15 (39.5%) 32 (42.1%) 
     Female 21 (55.3%) 23 (60.5%) 44 (57.9%) 
Race/Ethnicity    
     White 19 (50.0%) 21 (53.3%) 40 (52.6%) 
     Black/African American 15 (46.9%) 17 (53.1%) 32 (42.1%) 
     Other 4 (10.5%) 0 (0.0%) 4 (5.3%) 
Marital status    
     Single 18 (47.4%) 25 (65.8%) 43 (56.6%) 
     Married 4 (10.5%) 2 (5.2%) 6 (7.9%) 
Widowed 2 (5.3%) 2 (5.3%) 4 (5.3%) 
     Divorced/Separated 14 (36.8%) 9 (23.7%) 23 (30.2%) 
Education    
     Did not graduate high school 16 (40.8%) 15 (39.5%) 31 (40.8%) 
     Graduated high school 9 (23.7%) 10 (26.3%) 19 (25.0%) 
     Some college 8 (21.1%) 8 (21.1%) 16 (21.1%) 
     Technical/Associates degree 5 (13.2%) 4 (10.5%) 9 (11.8%) 
     Four years of college 0 (0.0%) 1 (2.6%) 1 (1.3%) 
Household income    
     <10,000 19 (50.0%) 21 (55.3%) 40 (52.6%) 
     10,000-19,999 11 (28.9%) 9 (23.7%) 20 (26.3%) 
20,000-29,999 2 (5.3%) 4 (10.5%) 6 (7.9%) 
30,000-39,999 2 (5.3%) 0 (0.0%) 2 (2.6%) 
     >40,000  4 (10.5%) 4 (10.5%) 8 (10.5%) 
Stages of Change    
Precontemplation 15 (39.5%) 12 (31.6%) 27 (35.5%) 
Contemplation 18 (47.4%) 21 (55.3%) 39 (51.3%) 
Preparation 5 (13.2%) 5 (13.2%) 10 (13.2%) 
Previous Attempt to Quit    
Yes 21 (59.2%) 24 (63.2%) 45 (59.2%) 
No 17 (44.7%) 14 (36.8%) 31 (40.8%) 
Chronic Pain Grade    
I 5 (13.2%) 7 (18.4%) 12 (15.8%) 
II 6 (15.8%) 6 (15.8%) 12 (15.8%) 
III 8 (21.1%) 9 (23.7%) 17 (22.4%) 
IV 19 (50.0%) 16 (42.1%) 35 (46.1%) 
Duration of Chronic Pain    
Less than 1 Year 10 (26.3%) 6 (15.8%) 16 (21.1%) 
1-3 Years 11 (28.9%) 6 (15.8%) 17 (22.4%) 
3-5 Years 2 (5.3%) 7 (18.4%) 9 (11.8%) 
5-10 Years 6 (15.8%) 6 (15.8%) 12 (15.8%) 
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More than 10 Years 9 (28.9%) 13 (34.2%) 22 (28.9%) 
Table 1. continued    
Frequency of Pain Medication Use    
Never/Rarely 14 (36.8%) 10 (27.0%) 24 (31.6%) 
1-3 Times/Month 0 (0.0%) 2 (5.3%) 2 (2.7%) 
1-2 Times/Week 6 (16.2%) 6 (15.8%) 12 (16.0%) 
Several Times/Week 5 (13.55) 4 (10.5%) 9 (12.0%) 
Daily 12 (32.4%) 16 (42.1%) 28 (37.3%) 
Prescription Opioid Misuse     
Yes 11 (28.96%) 11 (28.96%) 22 (28.9%) 
No 27 (71.1%) 27 (71.1%) 54 (71.1%) 
Willing to Learn about Cessation 
Treatment Options 
   
Yes 21 (55.3%) 23 (60.5%) 44 (57.9%) 
No 17 (44.7%) 15 (39.5%) 32 (42.1%) 
Interest in Using Cessation 
Treatment 
   
Yes 21 (55.3%) 19 (50%) 40 (52.6%) 
No 17 (44.7%) 19 (50%) 36 (47.4%) 
Intention to Engage Cessation 
Treatment 
   
Yes 9 (23.7%) 13 (34.2%) 22 (28.9%) 
No 29 (76.3%) 25 (65.8%) 54 (71.1%) 
    
 M (SD) M (SD) M (SD) 
Age 42.76 (13.41) 42.79 (13.61) 42.78 (13.42) 
Cigarettes per day 20.03 (13.24) 15.26 (6.76) 17.64 (10.71) 
Heaviness of Smoking Index 3.58 (1.08) 3.16 (1.31) 3.37 (1.21) 
Exhaled CO 14.39 (9.67) 17.03 (9.91) 15.69 (9.81) 
Years daily smoking 26.16 (13.44) 25.41 (12.20) 25.79 (12.76) 
Past-Year Quit Attempts 1.71 (4.01) 1.74 (2.05) 1.73 (3.16) 
Characteristic Pain Intensity 20.66 (4.63) 20.01 (5.74) 20.34 (5.19) 
Characteristic Disability 22.16 (10.61) 21.00 (10.90) 21.58 (10.70) 
Pain Days in Past 6 Months 128.05 (64.68) 123.60 (67.14) 125.83 (65.52) 
Pain-Related Anxiety 58.68 (23.72) 63.29 (25.60) 60.99 (24.62) 
Pain-Smoking Expectancies 2.63 (1.51) 2.94 (1.60) 2.79 (1.55) 
Alcohol Use 2.42 (3.05) 2.29 (3.25) 2.68 (3.14) 
Depression Symptoms 2.63 (2.11) 2.55 (2.13) 2.59 (2.12) 
Anxiety Symptoms 2.47 (1.91) 2.95 (2.13) 2.59 (2.01) 
Note. No significant differences were observed between treatment conditions.  
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Table 2 
 
Participant Responses to Items used to Assess Knowledge of Pain-Smoking Interrelations at 
Baseline, Post-Intervention, and One-Month Follow-Up 
 
 
Yes 
n (%) 
No 
n (%) 
Not Sure/ 
Don’t Know 
n (%) 
Baseline    
Can smoking cause chronic pain?    
Tailored 15 (39.5%) 1 (2.6%) 22 (57.9%) 
Control 16 (42.1%) 3 (7.9%) 19 (50.0%) 
Can smoking make pain worse over time?    
Tailored 17 (44.7%) 1 (2.6%) 20 (52.6%) 
Control 16 (42.1%) 2 (5.3%) 20 (52.6%) 
Can smoking make it more difficult to function physically 
despite pain? 
   
Tailored 24 (63.2%) 1 (2.6%) 13 (34.2%) 
Control 21 (55.3%) 2 (5.3%) 15 (39.5%) 
Can smoking reduce the effectiveness of prescription pain 
medications? 
   
Tailored 10 (26.3%) 2 (5.3%) 26 (68.4%) 
Control 9 (23.7%) 3 (7.9%) 26 (68.4%) 
Can the experience of pain make people want to smoke or 
cause them to smoke more? 
   
Tailored 27 (71.1%) 4 (10.5%) 7 (18.4%) 
Control 27 (71.1%) 3 (7.9%) 8 (21.1%) 
Can smoking directly reduce pain in a way that is similar to 
analgesic pain medications? 
   
Tailored 3 (7.9%) 19 (50.0%) 16 (42.1%) 
Control 5 (13.2%) 18 (47.4%) 15 (39.5%) 
Can smoking help to distract from pain?    
Tailored 22 (57.9%) 10 (26.3%) 6 (15.8%) 
Control 19 (50.0%) 9 (23.7%) 10 (26.3%) 
Can quitting smoking help to improve pain and physical 
function? 
   
Tailored 21 (55.3%) 2 (5.3%) 15 (39.5%) 
Control 23 (60.5%) 1 (2.6%) 14 (36.8%) 
    
Post-Intervention    
Can smoking cause chronic pain?    
Tailored 37 (97.4%) 0 (0.0%) 1 (2.6%) 
Control 17 (44.7%) 2 (5.3%) 19 (50.0%) 
Can smoking make pain worse over time?    
Tailored 38 (100.0%) 0 (0.0%) 0 (0.0%) 
Control 18 (47.4% 1 (2.6%) 19 (50.0%) 
Can smoking make it more difficult to function physically 
despite pain? 
   
Tailored 37 (97.4%) 0 (0.0%) 1 (2.6%) 
Control 19 (50.0%) 6 (15.8%) 13 (34.2%) 
Can smoking reduce the effectiveness of prescription pain 
medications? 
   
Tailored 36 (94.7%) 1 (2.6%) 1 (2.6%) 
Control 12 (31.6%) 5 (13.2%) 21 (55.3%) 
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Table 2. continued    
Can the experience of pain make people want to smoke or 
cause them to smoke more? 
   
Tailored 35 (92.1%) 2 (5.3%) 1 (2.6%) 
Control 26 (68.4%) 3 (7.9%) 9 (23.7%) 
Can smoking directly reduce pain in a way that is similar to 
analgesic pain medications? 
   
Tailored 20 (52.6%) 15 (39.9%) 3 (7.9%) 
Control 7 (18.4%) 15 (39.5%) 15 (42.1%) 
Can smoking help to distract from pain?    
Tailored 27 (71.1%) 9 (23.7%) 2 (5.3%) 
Control 24 (63.2%) 7 (18.4%) 7 (18.4%) 
Can quitting smoking help to improve pain and physical 
function? 
   
Tailored 31 (81.6%) 5 (13.2%) 2 (5.3%) 
Control 19 (50.0%) 5 (13.2%) 14 (36.8%) 
    
One-Month Follow-Up    
Can smoking cause chronic pain?    
Tailored 22 (88.0%) 1 (4.0%) 2 (8.0%) 
Control 15 (53.6%) 2 (7.1%) 11 (39.3%) 
Can smoking make pain worse over time?    
Tailored 24 (96.0%) 0 (0.0%) 1 (4.0%) 
Control 14 (50.0%) 1 (3.6%) 13 (46.4%) 
Can smoking make it more difficult to function physically 
despite pain? 
   
Tailored 23 (90.0%) 0 (0.0%) 2 (8.0%) 
Control 18 (64.3%) 5 (17.9%) 5 (17.9%) 
Can smoking reduce the effectiveness of prescription pain 
medications? 
   
Tailored 17 (68.0%) 1 (4.0%) 7 (28.0%) 
Control 11 (39.3%) 5 (17.9%) 12 (42.9%) 
Can the experience of pain make people want to smoke or 
cause them to smoke more? 
   
Tailored 19 (76.0%) 2 (8.0%) 4 (16.0%) 
Control 25 (89.3%) 1 (3.6%) 2 (7.1%) 
Can smoking directly reduce pain in a way that is similar to 
analgesic pain medications? 
   
Tailored 8 (32.0%) 11 (44.0%) 6 (24.0%) 
Control 5 (17.9%) 9 (32.1%) 14 (50.0% 
Can smoking help to distract from pain?    
Tailored 18 (72.0%) 3 (12.0%) 4 (16.0%) 
Control 19 (67.9%) 5 (17.9%) 4 (14.3%) 
Can quitting smoking help to improve pain and physical 
function? 
   
Tailored 19 (76.0%) 5 (20.0%) 1 (4.0%) 
Control 17 (60.7%) 2 (7.1%) 9 (32.9%) 
Note. Baseline and Post-Intervention N = 76; One-Month Follow-Up N = 59, 6 participants had missing data at One-
Month Follow-Up for some knowledge items.  
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Table 3 
 
Unadjusted Means and Standard Deviations of Continuous Outcome Variables  
at All Time Points 
 
    Baseline Post-Intervention One-Month Follow-Up 
  M (SD) M (SD) M (SD) 
Knowledge of Pain-Smoking 
Relations 
   
  Tailored  3.66 (1.82) 6.87 (1.21) 6.00 (1.96) 
  Control  3.58 (2.07) 3.74 (2.26) 4.43 (2.20) 
Contemplation Ladder     
  Tailored  5.08 (3.18) 6.87 (3.39) 6.96 (2.63) 
  Control  5.92 (2.87) 6.03 (2.95) 5.97 (2.87) 
Desire to Quit     
  Tailored  5.29 (2.97) 6.87 (3.19) 6.69 (2.68) 
  Control  5.74 (2.67) 6.08 (3.08) 6.52 (3.22) 
Expected Success in Quitting    
  Tailored  4.16 (2.51) 6.42 (2.99) 6.31 (2.88) 
  Control  4.32 (2.64) 4.89 (2.77) 5.16 (3.12) 
Anticipated Difficulty Quitting    
  Tailored  7.45 (2.90) 6.42 (2.87) 7.00 (2.86) 
  Control  7.00 (2.48) 6.53 (2.67) 7.55 (2.34) 
Readiness  to Quit    
  Tailored  4.11 (3.54) 5.84 (3.97) 5.50 (4.12) 
  Control  4.97 (3.29) 5.50 (3.34) 5.40 (3.95) 
Importance of Quitting    
  Tailored  6.55 (3.19) 7.24 (3.05) 8.73 (1.76) 
  Control  6.84 (2.80) 6.97 (2.93) 7.50 (2.60) 
Confidence  in Quitting    
  Tailored  3.11 (2.81) 4.55 (3.85) 5.19 (4.06) 
  Control  3.53 (3.12) 3.66 (2.98) 4.43 (2.20) 
Note. Baseline and Post-Intervention N = 76. One-Month Follow-Up N = 59. 
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Table 4 
 
Adjusted Means and Standard Errors of Continuous Outcome Variables at Post-Intervention 
 
 Intervention Condition 
 Tailored 
M (SE) 
Control 
M (SE) 
Knowledge of Pain-Smoking Relations*** 6.85 (0.24) 3.76 (0.24) 
Contemplation Ladder**  7.19 (0.32) 5.67 (0.32) 
Desire to Quit*  7.07 (0.31) 5.88 (0.31) 
Expected Success in Quitting** 6.46 (0.33) 4.83 (0.33) 
Anticipated Difficulty Quitting 6.36 (0.44) 6.59 (0.44) 
Readiness  to Quit 6.15 (0.45) 5.19 (0.45) 
Importance of Quitting 7.35 (0.29) 6.86 (0.29) 
Confidence in Quitting
†
 4.70 (0.44) 3.51 (0.44) 
Note. N = 76. Means and standard errors adjusted for baseline levels of each respective 
variable.  
*p < .01. **p = .001. ***p < .001. 
†
p = .059.  
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Table 5 
 
Intercorrelations between Measures of Motivation to Quit Smoking at Baseline 
 
 1. 2. 3. 4. 5. 6. 7. 
1. Contemplation Ladder -- .69*** .42*** .23* .76*** .78*** .55*** 
2. Desire to Quit  -- .60*** .23* .76*** .78*** .55*** 
3. Expected Success in 
Quitting 
  -- .01 .42*** .46*** .44*** 
4. Anticipated Difficulty 
Quitting 
   -- .08 .13 -.06 
5. Readiness to Quit     -- .66*** .67*** 
6. Importance of Quitting      -- .48*** 
7. Confidence in Quitting       -- 
Note. N= 76. 
*p < .01. ***p < .001. 
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Table 6  
 
Post-Intervention Willingness to Learn About, Interest in, and Intention to Engage Available 
Smoking Cessation Treatments 
 
 Intervention Condition  
 Tailored Control  
 n (%) n (%) OR [95% CI] 
Willing to learn about treatment 
resources 36 (94.7%) 28 (77.8%) 7.74 [1.49, 40.30]* 
    
Interested in using cessation 
treatment 36 (94.7%) 25 (65.8%) 9.55 [1.94, 47.02]** 
Talk to doctor/medication 32 (84.2%) 21 (55.3%) 4.27 [1.37, 13.28]* 
Quitline 29 (76.3%) 7 (18.4%) 18.81 [5.35, 66.07]* 
Behavioral Health 9 (23.7%) 1 (2.6%) 11.78 [1.40, 99.88]* 
    
Intention to engage treatment 
resources 30 (78.9%) 18 (47.4%) 5.15 [1.77, 14.96]** 
Talk to doctor/medication 25 (65.8%) 14 (36.8%) 4.04 [1.47, 11.09]** 
Quitline 22 (57.9%) 6 (15.8%) 9.80 [2.91, 33.02]*** 
Behavioral Health 3 (7.9%) 1 (2.6%) 2.91 [0.29, 29.43] 
Note. N = 76. Odds Ratio (OR) adjusted for baseline levels of each respective variable. 
*p < .05. **p < .01. ***p < .001. 
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Table 7 
 
Participant Comments about the Tailored Intervention  
 
Perceived Discrepancy  Participant Comment 
Yes being able to not have this chronic pain anymore 
 decrease in pain 
 I dont want to be in pain for the rest of my life 
 making my pain feel better 
 my pain 
 pain 
 Smoking and how it can worsen my pain 
 that my smoking does have a impact on my pain 
 that smoke can also cause pain 
 the information on how smoking was making my pain worst 
 the link between my chronic pain and smoking 
  
No about the brain and having to depend on others 
 all aspects 
 Because I’m not ready 
 carbon monoxide level 
 everything was helpfu 
 health 
 help factors available 
 mabey 
 more info on smoking 
 no desire to quit 
 no it did not.I dont want to quit 
 suffice info 
 not ready 
 talking about all the negative impacts of smoking 
 telling me my carbon levels are high 
 the scale 
 trying to understand why i smoke 
 yes 
 very much 
Note. Six participants did not provide a comment. All comments are exactly as typed by 
participants; spelling and grammatical errors have not been corrected.  
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Table 8 
 
Participant Satisfaction with the Tailored and Control Interventions  
 
 Intervention Condition 
 Tailored 
M (SD) 
Control 
M (SD) 
Quality of Service** 2.63 (0.49) 2.21 (0.66) 
Satisfaction with Service** 2.71 (0.46) 2.24 (0.79) 
Would Seek Services Again** 2.55 (0.60) 2.21 (0.81) 
Got Service You Wanted** 2.55 (0.56) 2.11 (0.65) 
Service Met Your Needs*** 2.45 (0.72) 1.76 (0.75) 
Recommend Service to a Friend* 2.71 (0.46) 2.24 (0.71) 
Satisfaction with Amount of Help Received* 2.55 (0.76) 2.16 (0.92) 
Services Helped You Deal More Effectively 
with Problems** 
2.45 (0.60) 1.95 (0.70) 
Note. All response scales 0-3, with higher scores representing greater satisfaction.  
*p < .05. **p < .01. ***p < .001.  
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Figure 1. Study timeline.  
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Figure 2. Participant flow chart following CONSORT guidelines.  
 
Assessed for eligibility (n = 160) 
Excluded (n = 84) 
   Not meeting inclusion criteria (n = 66) 
   Eligible but did not enroll (e.g., 
declined to participate; did not 
attend first session; n = 18)  
Analysed   
 Post-Intervention Outcomes (n = 38) 
 One-Month Follow-Up Outcomes (n = 27) 
 Excluded due to loss to follow-up (n = 11) 
 
Lost to follow-up (n = 11) 
 Number not in service (n = 6) 
 Did not return multiple voicemails (n = 3) 
 Did not answer multiple calls/no voicemail (n = 1) 
 Moved away (n = 1) 
 
Allocated to tailored intervention (n = 38) 
 Received allocated intervention (n = 38) 
Lost to follow-up (n = 6) 
 Number not in service (n = 2) 
 Did not return multiple voicemails (n = 3) 
 Did not answer multiple calls/no voicemail (n = 1) 
 
Allocated to control intervention (n = 38) 
 Received allocated intervention (n = 38) 
Analysed   
 Post-Intervention Outcomes (n = 38) 
 One-Month Follow-Up Outcomes (n = 32) 
 Excluded due to loss to follow-up (n = 6) 
 
 
Allocation 
Analysis 
Follow-Up 
Enrolled and Randomized (n = 76) 
Enrollment 
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Figure 3.  Post-intervention mean (adjusted) knowledge of pain-smoking interrelations and 
motivation to quit as a function of intervention condition. Error bars represent standard error.  
* p < .01. ** p = .001. *** p < .001. 
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Figure 4. Conceptual model of indirect associations between the tailored intervention and greater 
post-intervention desire to quit and willingness to accept information about cessation treatment 
via increased knowledge of pain-smoking interrelations. X = independent variable. M = 
mediating variable. Y = Dependent Variable. C = Covariate. 
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Appendix A 
 
Measures 
 
Screening Items 
 
1. Do you now smoke cigarettes (read choices): 
______ Not at all  
______ Some Days  
______ Every Day  
 
2. Over the last week, how many cigarettes did you smoke per day on average? __________ 
 
3. Are you currently in treatment to help you quit smoking. By treatment I mean seeing a 
counselor or therapist, using the quitline, or using a smoking cessation medication like 
patches or gum. Check all that apply: 
______ No   
______ Yes, using medication, Clarify type of medication ____________________  
______ Yes, seeing counselor or therapist 
______ Yes, Quitline   
 
4. How much bodily pain have you had during the past 4 weeks? (read choices) 
______ None   
______ Mild  
______ Moderate 
______ Severe 
______ Very Severe 
 
5. Do you currently suffer from any type of chronic pain, that is, pain that occurs constantly or 
flares up frequently? Do not report aches or pains that are fleeting or minor 
______ No   
______ Yes 
 
6. Using a 0 – 10 scale, where 0 is “no pain” and 10 is “pain as bad as could be”… During the 
last 3 months, ON AVERAGE, how would you rate your pain?  
No Pain        
Pain as bad 
as could be 
0 1 2 3 4 5 6 7 8 9 10 
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Thoughts About Abstinence Scale 
 
First, I’d like to know how you feel about stopping smoking cigarettes at this time. On a scale 
from 1 to 10, with 1 representing no desire to quit and 10 representing full desire to quit, give 
yourself a rating. Chose the number between 1 and 10 that best describes your own desire to stop 
smoking cigarettes at this time. Remember, the higher the number, the greater your desire. 
 No Desire to Quit    1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Full Desire to Quit  10 
 
Now I’d like to know how successful you expect to be quitting smoking cigarettes at this time. 
Be realistic about this, based on your past experiences and your present strength of motivation. 
On a scale from 1 to 10, with 1 representing the lowest expectation of success and 10 
representing the highest expectation of success, give yourself a rating of your own expectation of 
success in quitting smoking cigarettes. Remember, the higher the number the greater the 
expectation of success.  
 Lowest Expectation of Success  1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Highest Expectation of Success  10 
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Now I’d like to know how difficult you think it will be for you to keep from smoking cigarettes 
after having quit. On a scale from 1 to 10, with 1 representing the lowest amount of difficulty 
and 10 representing the greatest amount of difficulty, give yourself a rating of how difficult you 
think it will be for you to quit and remain abstinent. Remember, the higher the number, the more 
difficult you think it will be for you to quit. 
 Lowest Amount of Difficulty  1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Highest Amount of Difficulty  10 
 
Lastly, I want to know the GOAL you have chosen for yourself about smoking cigarettes at this 
time. Please read the goals listed on this page and circle the one goal that best represents your 
own goal at this time, and fill in blanks as indicated.  
 I really don't have a clear goal in mind. 
 I want to use cigarettes in a controlled manner – to be in control of how often I smoke and 
how much I smoke. I would like to limit that to no more than _____ (amount) per _____ 
(time). ____________________ 
 I want to be totally abstinent from all cigarette use for a period of time, after which I will 
make a new decision about whether or not I will smoke cigarettes again. For me, the time 
period I want to be abstinent for is: ____________________ 
 I don’t want smoking cigarettes to be a habit for me anymore, but I would like to be able to 
occasionally smoke cigarettes when I really have an urge. 
 I want to quit smoking cigarettes once and for all, even though I realize I may slip up and 
smoke cigarettes once and a while. 
 I want to quit smoking cigarettes once and for all, be totally abstinent, and never smoke 
cigarettes ever again for the rest of my life. 
 None of the above applies exactly to me. My own goal is: ____________________ 
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Contemplation Ladder 
 
Each rung on this ladder represents where various smokers are in their thinking about quitting.  
Click on the number that indicates where you are now.  Please select only one number. 
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Motivation Rulers 
 
How important is stopping smoking to you? 
 Not Important at All  0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Most important goal of my life  10 
 
How ready are you to quit smoking within the next month? 
 Not at All Ready  0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 100% Ready  10 
 
How confident are you that you will quit smoking within the next month? 
 Not at All Confident  0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 100% Confident  10 
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Pain and Smoking Questionnaire 
 
Below are a series of questions about relations between tobacco smoking and various health 
conditions. We are interested in what you have already learned or know to be true (yes/no) 
versus what you may not yet know or be sure about (not sure/don't know). In other words, these 
questions are not asking about your opinions on these topics, but rather what you do or do not 
know to be true according to scientific research findings. 
 
Please indicate whether smoking has been associated with each of the following health 
problems/conditions: 
 Yes No Not Sure/Don't Know 
Lung Cancer       
Chronic Obstructive 
Pulmonary Disease 
(COPD) 
      
Heart Disease       
Oral Disease       
Pregnancy 
Complications 
      
Infertility       
HIV       
Chronic Pain       
Diabetes       
 
 
Please indicate whether smoking is a known risk factor for each of the following health 
problems/conditions: 
 Yes No Not Sure/Don't Know 
Lung Cancer       
Heart Disease       
Chronic Pain       
Diabetes       
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Has any health care provider ever talked to you about relationships between: 
 Yes No Not Sure/Don't Know 
Smoking and lung 
cancer 
      
Smoking and heart 
disease 
      
Smoking and chronic 
pain 
      
Smoking and diabetes       
 
 
Can smoking cause chronic pain? 
 Yes 
 No 
 Not Sure/Don't Know 
 
Can smoking make pain worse over time? 
 Yes 
 No 
 Not Sure/Don't Know 
 
Can smoking make it more difficulty to function physically despite pain? 
 Yes 
 No 
 Not Sure/Don't Know 
 
Can smoking reduce the effectiveness of prescription pain medications? 
 Yes 
 No 
 Not Sure/Don't Know 
 
Can the experience of pain make people want to smoke or cause them to smoke more? 
 Yes 
 No 
 Not Sure/Don't Know 
 
Can smoking directly reduce pain in a way that is similar to analgesic pain medications? 
 Yes 
 No 
 Not Sure/Don't Know 
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Can smoking help to distract from pain? 
 Yes 
 No 
 Not Sure/Don't Know 
 
Can quitting smoking help to improve pain and physical functioning? 
 Yes 
 No 
 Not Sure/Don't Know 
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Cessation Treatment Engagement 
 
Would you like to learn about options for treatment to help you quit smoking? 
 No 
 Yes 
 
Are you interested in learning more about (Check all that apply) 
 Medication/Primary Care 
 Quitline 
 Behavioral Health 
 None of the Above 
 
Do you PLAN TO ENROLL in any treatment in the next 30 days? (Check all that apply) 
 Medication/Primary Care 
 Quitline 
 Behavioral Health 
 None of the Above 
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Demographics Form 
 
The following questions are about yourself and your life situation. All answers will be kept 
confidential. 
 
Gender  
 Male 
 Female 
 
What is your age? 
 
Date of Birth (mm/dd/yyyy) 
 
What is your marital status? (Choose one) 
 Single 
 Married 
 Separated 
 Divorced 
 Widowed 
 
With which racial category do you most identify yourself? (Choose one) 
 American Indian/Alaska Native 
 Asian 
 Native Hawaiian or Other Pacific Islander 
 Black or African American 
 White 
 Other ____________________ 
 
Are you Hispanic/Latino? 
 Yes 
 No 
 
What is the highest grade level you have completed? (Choose one) 
 Did not graduate high school 
 High school graduate 
 Some college 
 Technical school/Associates degree 
 4-year college degree 
 Some school beyond 4-year college degree 
 Professional degree (e.g. MD, JD, PhD) 
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What is your total household income? (Choose one) 
 Under $10,000 
 $10,000-$19,999 
 $20,000-$29,999 
 $30,000-$39,999 
 $40,000-$49,999 
 $50,000-$59,999 
 $60,000-$69,999 
 $70,000-$79,999 
 $80,000-$89,999 
 Over $90,000 
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Heaviness of Smoking Index 
 
How soon after you wake up do you smoke your first cigarette? 
 Within 5 minutes 
 6-30 minutes 
 31-60 minutes 
 After 60 minutes 
 
How many cigarettes per day do you smoke? 
 10 or less 
 11 - 20 
 21 - 30 
 31 or more 
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Smoking History Form 
 
How old were you when you started smoking? 
 
For how many years, altogether, have you been a regular/daily smoker? 
 
Over the last week, how many cigarettes did you smoke per day on average? 
 
Have you ever made a serious attempt to quit smoking? 
 Yes 
 No 
 
How many different times in the past year have you made a serious attempt to quit smoking and 
stayed off cigarettes for 24 hours or more? 
 
How many different times in your life have you made a serious attempt to quit smoking and 
stayed off cigarettes for 24 hours or more? 
 
What is the longest period of time that you have ever been able to quit smoking? Please select 
one answer. 
 Hours ____________________ 
 Days ____________________ 
 Months ____________________ 
 Years ____________________ 
 
How hard was it for you to quit smoking on your most recent quit attempt? 
 Easy 
 Slightly Difficult 
 Difficult 
 Very Difficult 
 
If you quit smoking now, how confident are you that you could go without smoking for 
 No Confidence A little 
Confidence 
Moderately 
Confident 
Very Confident Extremely 
Confident 
One Week           
One Month           
One Year           
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Do you currently use any other forms of nicotine or tobacco? (Select all that apply) 
 I do not use any other forms of nicotine or tobacco 
 Cigar or cigarillo 
 Smokeless tobacco (e.g., chew, dip, snus, snuff) 
 Pipe tobacco 
 Hookah 
 Electronic Cigarette (e-cig) or Nicotine Vaporizer 
 Nicotine gum, patch, or lozenge 
 Other (please specify) ____________________ 
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Stages of Change Algorithm 
 
In the last year, how many times have you quit smoking for at least 24 hours? 
 
Are you seriously thinking of quitting smoking? 
 No, not thinking of quitting 
 Yes, within the next 6 months 
 Yes, within the next 30 days 
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Pain and Smoking Inventory 
 
Below are a series of statements about ways that pain may be related to cigarette smoking. Please 
rate your level of agreement for each using the following scale:  
 
 Not true at 
all  0 
1 2 Somewhat 
true  3 
4 5 Extremely 
true  6 
1. Smoking helps me 
cope with my pain. 
              
2. The number of 
cigarettes I smoke per 
day is often influenced by 
my pain. 
              
3. When my pain flares 
up I want to have a 
cigarette. 
              
4. My pain makes me less 
confident that I could 
stop smoking for good. 
              
5. Smoking a cigarette 
helps me think about 
something other than my 
pain. 
              
6. My pain would 
interfere with any attempt 
I make to quit smoking. 
              
7. Feeling pain makes me 
want to smoke. 
              
8. My pain prevents me 
from trying to quit 
smoking. 
              
9. Smoking helps me 
cope with the stress and 
unhappiness that comes 
with pain. 
              
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Graded Chronic Pain Scale 
 
On how many days in the last 180 days (6 months) have you had pain? 
 
How would you rate your pain RIGHT NOW?  
 No Pain  0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Pain as bad as could be  10 
 
In the last 3 months, how would you rate your WORST pain? 
 No Pain  0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Pain as bad as could be  10 
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In the last 3 months, ON AVERAGE, how would you rate your pain? 
 No Pain  0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Pain as bad as could be  10 
 
In the last 3 months, how many days did pain keep you from doing DAILY ACTIVITIES (work, 
school, homework)? 
 None 
 1 
 2 
 3-4 
 5-6 
 7-10 
 11-15 
 16-24 
 25-60 
 61-75 
 76-90 
 
In the last 3 months, how much has pain interfered with your DAILY ACTIVITIES? 
 No Interference  0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Unable to carry on any activities  10 
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In the last 3 months, how much has pain interfered with your RECREATIONAL, SOCIAL, & 
FAMILY ACTIVITIES? 
 No Interference  0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Unable to carry on any activities  10 
 
In the last 3 months, how much has pain interfered with your ABILITY TO WORK, including 
housework? 
 No Interference  0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 Unable to carry on any activities  10 
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Pain History 
 
How long have you been experiencing chronic pain? 
 Less than 3 months 
 4 to 6 months 
 7 to 12 months 
 Over 1 year to 3 years 
 Over 3 years to 5 years 
 Over 5 years to 10 years 
 Over 10 years 
 
How old were you when you first experienced this type of pain? 
 
How often do you experience this pain? 
 It's constant, always there 
 At least once a day 
 At least once a week 
 Not every week, but at least once a month 
 Less often 
 
What is the cause of your pain 
 Chronic Back Pain 
 Chronic Low Back Pain 
 Chronic Neck Pain 
 Frequent or Severe Headaches 
 Cluster Headaches 
 Migraines 
 Arthritis/Rheumatism 
 Fibromyalgia 
 Musculoskeletal Pain 
 Neuropathic Pain 
 Other ____________________ 
 
Do you currently have medically unexplained chronic pain? This is defined as pain lasting six 
months or longer that is severe enough to either interfere a lot with your normal activities or to 
cause a lot of emotional distress and that a doctor cannot find a physical cause to explain.  
 Yes 
 No 
 
How many doctors have you seen about your pain? 
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How satisfied are you with how your doctor is helping you manage your pain? 
 Very Satisfied 
 Satisfied 
 Dissatisfied 
 Very dissatisfied 
 I have not seen my doctor about pain. 
 
Have you received treatment from a pain specialist or pain treatment program? 
 Yes, previously 
 Yes, currently 
 No 
 
How satisfied are you with how your pain specialist/pain treatment program is helping you 
manage your pain? 
 Very Satisfied 
 Satisfied 
 Dissatisfied 
 Very Dissatisfied 
 I have never received treatment from a pain specialist/pain treatment program. 
 
How often do you take any medication to treat your pain? 
 Daily 
 Several times a week 
 One or two times a week 
 One to three times a month 
 Rarely 
 Never 
 
What types of medication are you taking for your pain (Check all that apply)?   
 Over the counter non steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen or 
naproxen) 
 Over the counter pain relievers such as aspirin or acetaminophen 
 Over the counter topical treatments (patch, cream) 
 Prescription nonsteroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen or naproxen) 
 Prescription pain relievers such as aspirin or acetaminophen 
 Prescription topical treatments (patch, cream) 
 Prescription opioid/narcotic medication (e.g., OxyContin, Percocet, Vicodin) 
 I do not ever take medication for my pain 
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Pain Anxiety Symptoms Scale 
 
Please rate how often you do each of these things when you are in pain using the following scale:  
  
 Never  
0 
1 2 Some- 
times  3 
4 5 Always  
6 
1. I think that if my pain gets too severe, it will 
never decrease. 
              
2. When I feel pain I am afraid that something 
terrible will happen. 
              
3. I go immediately to bed when I feel severe pain.               
4. I begin trembling when engaged in an activity 
that increases pain. 
              
5. I can’t think straight when in pain.               
6. I will stop any activity as soon as I sense pain 
coming on. 
              
7. Pain seems to cause my heart to pound or race.               
8. As soon as pain comes on I take medication to 
reduce it. 
              
9. When I feel pain I think I might be seriously ill.               
10. During painful episodes it is difficult for me to 
think of anything besides the pain. 
              
11. I avoid important activities when I hurt.               
12. When I sense pain I feel dizzy or faint.               
13. Pain sensations are terrifying.               
14. When I hurt I think about pain constantly.               
15. Pain makes me nauseous.               
16. When pain comes on strong I think that I might 
become paralyzed or more disabled. 
              
17. I find it hard to concentrate when I hurt.               
18. I find it difficult to calm my body down after 
periods of pain. 
              
19. I worry when I am in pain.               
20. I try to avoid activities that cause pain.               
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Prescription Opioid Misuse Index 
 
Please answer the following questions regarding your use of prescription analgesic/opioid 
medications only. 
 
Do you ever use MORE of your medication, that is, take a higher dosage, than is prescribed for 
you? 
 Yes 
 No 
 
Do you ever use your medication MORE OFTEN, that is, shorten the time between dosages, than 
is prescribed for you?  
 Yes 
 No 
 
Do you ever need early refills for your pain medication? 
 Yes 
 No 
 
Do you ever feel high or get a buzz after using your pain medication? 
 Yes 
 No 
 
Do you ever take your pain medication because you are upset, using the medication to relieve or 
cope with problems other than pain? 
 Yes 
 No 
 
Have you ever gone to multiple physicians including emergency doctors, seeking more of your 
pain medication? 
 Yes 
 No 
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Patient Health Questionnaire-4 
 
Over the past 2 weeks have you been bothered by any of the following problems? 
 0 1 2 3 
Feeling nervous, 
anxious, or on 
edge. 
        
Not being able to 
stop or control 
worrying. 
        
Little interest or 
pleasure in doing 
things. 
        
Feeling down, 
depressed, or 
hopeless. 
        
 
 
  
71 
 
 
 
Alcohol Use Disorders Identification Test-C 
 
Think about your drinking over the past year. Please select the response that represents the best 
answer for you.     One standard drink is equal to:     12 Oz Beer or Wine Cooler  5 Oz Glass of 
Wine  1.5 Oz Distilled Spirits    
 
How often do you have a drink containing alcohol? 
 Never 
 Monthly 
 2-4 times a month 
 2-3 times a week 
 4 or more times a week 
 
How many drinks containing alcohol do you have on a typical day when you are drinking? 
 0, I do not drink alcohol 
 1 or 2 
 3 or 4 
 5 or 6 
 7 to 9 
 10 or more 
 
How often do you have six or more drinks on one occasion? 
 Never 
 Less than Monthly 
 Montly 
 Weekly 
 Daily or Almost Daily 
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Previous Smoking Cessation Treatment 
 
Have you ever received services to help you quit smoking? 
 No 
 Yes, I received counseling or therapy 
 Yes, I received medication 
 Yes, I called the Quitline 
 Yes, I talked to my doctor 
 Yes, I attended the VA QuitSmart Program 
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Client Satisfaction Questionnaire 
 
Please tell us about the services you have received to help you quit smoking. We are interested in 
your honest opinions, whether they are positive or negative. Please answer all of the questions. 
We also welcome your comments and suggestions.  
 
How would you rate the quality of service you received? 
 Poor 
 Fair 
 Good 
 Excellent 
 
Did you get the kind of service you wanted? 
 No, definitely not 
 No, not really 
 Yes, generally 
 Yes, definitely 
 
To what extent did the services meet your needs? 
 None of my needs have been met 
 Only a few of my needs have been met 
 Most of my needs have been met 
 Almost all of my needs have been met 
 
If a friend were in need of similar help, would you recommend the services to him/her? 
 No, definitely not 
 No, I don't think so 
 Yes, I think so 
 Yes, definitely 
 
How satisfied are you with the amount of help you received? 
 Very Dissatisfied 
 Mildly Dissatisfied 
 Mildly Satisfied 
 Very Satisfied 
 
Have the services you received helped you to deal more effectively with your problems? 
 No, they seemed to make them worse 
 No, they didn't really help 
 Yes, they helped somewhat 
 Yes, they helped a great deal 
 
74 
 
 
 
In an overall general sense, how satisfied are you with the services you received? 
 Very Dissatisfied 
 Mildly Dissatisfied 
 Mildly Satisfied 
 Very Satisfied 
 
If you were to seek help again, would you use these services again? 
 No, definitely not 
 No, I don't think so 
 Yes, I think so 
 Yes, definitely 
 
Write additional comments below 
 
 
On a scale from 1 to 5, rate how helpful you felt the handout was? 
 Not at all helpful  1 
 2 
 3 
 4 
 Extremely helpful  5 
 
What parts of the handout did you like best? 
 
What parts of the handout did you not like? 
 
On a scale from 1 to 5, rate how understandable you felt the handout was? 
 Not at all understandable  1 
 2 
 3 
 4 
 Extremely understandable  5 
 
Were there any things you would recommend changing to improve the understandability of the 
handout? 
 
Did you feel the meeting with me helped improve your motivation to quit smoking? 
 Yes; if so, what aspects of the meeting led you to want to quit? ____________________ 
 No; if so, why not? ____________________ 
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On a scale from 1 to 5, rate how satisfied you would be with the format of the discussion if you 
were meeting with me at your doctors office after reporting that you are a current smoker?  
 Not at all satisfied  1 
 2 
 3 
 4 
 Extremely satisfied  5 
 
Would you prefer to have the discussion over the phone instead of in person? 
 Yes 
 No 
 
Would you prefer to have the discussion over the internet instead of in person?  
 Yes 
 No 
 
On a scale from 1 to 5, rate how satisfied you would be with the length of time of the discussion? 
 Not at all satisfied  1 
 2 
 3 
 4 
 Extremely satisfied  5 
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Smoking Behavior at One-Month Follow-Up  
 
Do you now smoke cigarettes? 
 Not at all 
 Some Days 
 Every Day 
 
Over the last week, how many cigarettes did you smoke per day on average?  
 
In the past month, have you cut down on your smoking? 
 Yes 
 No 
 
In the past month, did you quit smoking for at least 24 hours? 
 Yes (if yes, how many times?) ____________________ 
 No 
 
In the past month, did you talk to your doctor about your smoking? 
 Yes 
 No 
 
In the past month, did you start using a medication to help you quit smoking? (check all that 
apply) 
 No 
 Over the Counter NRT (patch, gum, lozenge) 
 Prescription NRT (inhaler, spray) 
 Non-NRT Prescription (Chantix/Zyban) 
 
In the past month, did you see a behavioral health provider about your smoking? 
 Yes 
 No 
 
In the past month, did you call the quitline? 
 Yes 
 No 
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Appendix B 
 
Therapist Guide for the Tailored Intervention 
 
Intervention Component: Personalized Feedback  
Rationale  
 Feedback about personal risk and impairment is an essential component of brief substance use interventions 
(SAMHSA, 2012). 
 Personalized feedback is a component of existing evidence-based motivational smoking interventions (e.g., 
Emmons, 2007).  
Content 
 Smoking History (e.g., tobacco dependence, baseline motivation to quit) 
 Pain Complaint (e.g., pain intensity, pain-related disability) 
 Pain-Smoking Expectancies (e.g., smoking as a means for pain coping) 
 
Intervention Component: Pain-Smoking Psychoeducation  
Rationale 
 According to the Health Belief Model, individuals are more likely to change an unhealthy behavior if they 
believe that (a) they are susceptible to negative health outcomes, (b) the negative health outcomes will be 
severe in nature, and (c) behavior change will be effective in alleviating or reducing these negative 
outcomes (Champion & Skinner, 2008).  
 Providing smokers with a clear and explicit link between smoking and illness has been shown to increase 
motivation to quit (McCaul et al., 2006).  
Content  
 Reciprocal relations between pain and smoking 
 Evidence that smoking may: 
o Cause chronic pain 
o Increase pain intensity and disability over time  
o Interfere with pain treatment  
 Smoking in order to cope with pain may lead to worse pain outcomes 
 Smokers may experience clinically meaningful  improvement in pain severity after quitting 
 
Intervention Component: Develop Discrepancy between Smoking and Desired Pain Outcomes 
Rationale  
 The Transtheoretical Model (e.g., Prochaska & DiClemente, 1983) predicts that smokers may be motivated 
to progress towards behavior change as they come to perceive discrepancy between positive and negative 
effects of smoking. 
 Developing discrepancy between continued smoking and desired outcomes is a core component of existing 
evidence-based motivational smoking interventions (e.g., Emmons, 2007).  
 The “5 R’s” (relevance, risk, reward, roadblock, repetition) are recommended by Clinical Practice 
Guidelines as a brief motivational smoking intervention (Fiore et al., 2008)  
Content 
 Elicit desired pain outcomes 
 Risks/benefits of smoking with an emphasis on pain outcomes 
 “5 R’s”  
o Relevance of quitting to pain and desired pain outcomes 
o Risks of continued smoking to pain and pain outcomes 
o Rewards of quitting for pain and pain outcomes 
o Roadblocks to quitting; engagement of smoking cessation treatment to address roadblocks 
o Repetition (smoking requires repeated attempts to quit, engagement of smoking cessation 
treatment can assist future quit attempts and improve chances of success) 
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You might be interested to know …  
 Smoking causes chronic pain! 
 Smoking makes pain worse over time! 
 Smoking can interfere with pain treatment! 
Even if pain makes some people want to smoke… 
 Smoking to cope with pain has been linked 
to worse pain over time! 
But… there’s GOOD NEWS! 
 
People who quit smoking have lower 
pain and can get back to doing the 
things they enjoy! 
Appendix C 
 
Psychoeducation Handout for the Tailored Intervention 
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Appendix D 
 
Therapist Guide for the Control Intervention 
 
All components of the control intervention are consistent with the US Department of Health and Human Services 
Clinical Practice Guidelines (Fiore et al., 2008) recommendations for the 3As (i.e., Ask, Advise, Arrange) brief 
smoking intervention.  
 
Intervention Component: Ask  
Rationale 
 Clinical Practice Guidelines recommends that all smokers be asked about current smoking (Fiore et al., 
2008)  
Content 
 Assess current smoking behavior 
 Assess readiness to quit smoking 
 
Intervention Component: Advise 
Rationale 
 Clinical Practice Guidelines recommend that all smokers be advised to quit smoking (Fiore et al., 2008) 
Content 
 Provide advice to quit smoking  
 
Intervention Component: Arrange  
Rationale 
 Clinical Practice Guidelines recommend that all smokers be who are interested in have follow-up arranged 
(Fiore et al., 2008) 
Content 
 Provide Clearing the Air (National Cancer Institute) 
 Offer information about other treatment resources 
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Appendix E 
 
Tailored Intervention Fidelity Checklist  
 
1. Did the interventionist provide personalized feedback? (Check all that apply) 
 ___ Smoking History 
 ___ Pain Complaint 
 ___ Pain-Smoking Expectancies  
 
2. Did the interventionist provide psychoeducation about pain-smoking interrelations? (Check all 
that apply) 
___ Reciprocal Relations between Pain and Smoking 
___ Effects of Smoking on Pain  
 ___ Effects of Smoking to Cope with Pain  
 ___ Effects of Quitting Smoking on Pain 
 
3. Did the interventionist develop discrepancy between smoking and desired pain outcomes? 
(Check all that apply) 
 ___ Elicit Desired Pain Outcomes 
 ___ Risks/benefits of Smoking 
 ___ 5Rs (relevance, risks, rewards, roadblocks, repetition) 
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Appendix F 
 
Control Intervention Fidelity Checklist 
 
1. Did the interventionist ask about smoking? (Check all that apply) 
 ___ Current Smoking Behavior 
 ___ Readiness to quit 
  
2. Did the interventionist provide advice to quit smoking?  
___ Yes 
___ No  
 
3. Did the interventionist offer assistance/resources for quitting?  
 ___ Yes 
 ___ No 
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Appendix G 
 
Smoking Cessation Resources Handout 
 
Interested in quitting smoking?  
 
Services are available to help you quit.  
 
New York State Smokers’ Quitline  
 1-866-NY-QUITS (1-866-697-8487) 
o Mon-Thurs: 9 a.m. - 9 p.m. 
o Fri, Sat and Sun: 9 a.m. - 5 p.m. 
 Check them out online at www.nysmokefree.com 
 
Smoking Cessation Medication  
 Your doctor can help determine which medication is best for 
you.  
 Medication options include: 
o Over-the-counter nicotine replacement therapy 
(patches, gum, lozenges) 
o Prescription nicotine replacement therapy (inhaler, 
nasal spray) 
o Non-nicotine prescription medication (bupropion/Zyban 
and varenicline/Chantix).   
 Talk to your doctor to learn more about medications for 
smoking cessation.  
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